Mathematical modeling in understanding NFkB signaling pathway by Liu, Huanling
Graduate Theses, Dissertations, and Problem Reports 
2010 
Mathematical modeling in understanding NFkB signaling pathway 
Huanling Liu 
West Virginia University 
Follow this and additional works at: https://researchrepository.wvu.edu/etd 
Recommended Citation 
Liu, Huanling, "Mathematical modeling in understanding NFkB signaling pathway" (2010). Graduate 
Theses, Dissertations, and Problem Reports. 4627. 
https://researchrepository.wvu.edu/etd/4627 
This Thesis is protected by copyright and/or related rights. It has been brought to you by the The Research 
Repository @ WVU with permission from the rights-holder(s). You are free to use this Thesis in any way that is 
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain 
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license 
in the record and/ or on the work itself. This Thesis has been accepted for inclusion in WVU Graduate Theses, 
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. 
For more information, please contact researchrepository@mail.wvu.edu. 
 
 





Thesis submitted to the  
College of Engineering and Mineral Resources  
at West Virginia University  
in partial fulfillment of the requirements  
for the degree of  




David J. Klinke, Ph.D., Chair 
Charter D. Stinespring, Ph.D. 
Robin Hissam, Ph.D. 
 
Morgantown, West Virginia 
2010 
Keywords: 3,4-dichloropropionanilide, NFкB, Macrophages, Mathematical 
Modeling, Statistic Analysis 
 
ABSTRACT 
Mathematical modeling in understanding NFкB signaling pathway 
Huanling Liu 
Chronic diseases, cancers and diabetes are associated with dysregulation of many 
biochemical cues. These biochemical cues are proteins that regulate cellular activity 
migration and death. The synthesis of these proteins is regulated by nuclear transcription 
factors. One of the most studied transcription factor is nuclear factor kappa B (NFкB). 
Many different proteins have been identified that regulate the activity of NFкB. Yet, how 
these proteins regulate NFкB is still unclear. 
Understanding the regulation of NFкB is important for developing drugs to treat these 
diseases. Our long term goal is to understand the mechanisms that regulate NFкB activity. 
The goal of this research is to identify how NFкB activity is regulated. As a model 
system, we will use LPS to stimulate macrophage cells with or without 3, 4-
dichloropropionanilide (DCPA) treatment. DCPA is a post-emergent herbicide used for 
controlling weeds in rice crops. Exposure to DCPA causes increases in liver and spleen 
weight demonstrated by toxicity study on rats. Previous study in our lab showed that 
DCPA could modulate NFкB activity. Our central hypothesis is that a mathematical 
model can be used to infer the regulation steps that are altered following DCPA treatment. 
To test our central hypothesis, we performed the following specific aim: 
Establish that NFкB is differentially regulated by IкBα and IкBβ and  that these proteins 
are in turn differentially regulated by DCPA. Moreover, a mathematical model was used 
to establish observed dynamics of NFкB activities. Our working hypothesis is that an 
ordinary differential equation (ODE)-based model that includes NFкB regulation by IкBα 
proteins can capture the observed dynamics. Furthermore, we used an empirical Bayesian 
approach to establish confidence in model parameters.  Then, we included IкBβ in the 
model to more realistically describe the regulation of NFкB activity in macrophages.   
We expect that the results of this research will lead to greater understanding of the 
regulatory mechanism of NFкB signaling pathway in macrophages and have important 
implication for human health. This improved understanding may also inspire new ideas to 
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1.1 Nuclear factor kappa B 
Chronic diseases, cancers and diabetes are associated with dysregulation of many 
biochemical cues [1, 2]. These biochemical cues are proteins that regulate cellular 
activity migration and death. The synthesis of these proteins is regulated by nuclear 
transcription factors. One of the most studied transcription factors is nuclear factor kappa 
B (NFкB), which plays an important role in regulating the expression of various 
inflammatory mediators [3,4,5]. Inflammatory mediators are released by immune cells 
during times when harmful agents invade our body. Immune cells like macrophages can 
recognize the bacterial cell wall components, such as lipopolysaccharide (LPS), and 
secret inflammatory mediators like TNFα and IL-1. In rheumatoid arthritis patients, 
inflammatory mediators like TNFα and IL-1 are secreted by primarily macrophages and 
also upregulated by NFкB.  Then TNFα and IL-1 activate NFкB in a wide variety of cells 
to produce more inflammatory mediators inducing cytokines [41]. Roy L and co-workers 
[42] observed that pro-arthritic mice had significant increase in breast cancer-associated 
secondary metastasis compared to non-arthritic mice. Increased inflammatory mediators 
like IL-6, TNFα and IL-17 were measured on arthritic mice and were suggested as the 
underlying factors that are responsible for the increased metastasis in the arthritic mice. 
NFкB was also observed constitutively active in mononuclear cells from patients with 
type 1 diabetes and some cancers [1, 4]. For inflammation-associated cancers, activity of 
NFкB was proposed to enhance tumor development by promoting inflammation. 
Therefore, understanding the regulatory mechanisms for NFкB activity is important for 
treating these diseases [6]. 
3,4-dichloropropionanilide (DCPA), which is also known as propanil, is a common 
herbicide for control of weeds on commercial rice crops worldwide. DCPA has been 
demonstrated suppressing inflammatory mediator TNFα production by macrophage 





the mechanism of DCPA suppressing macrophage functions by Frost and coworkers [29] 
demonstrated that DCPA treatment decreases NFкB nuclear localization and DNA 
binding in IC-21 cells following 10 g/ml LPS stimulation. A simple mathematical 
model was built to display the effect of DCPA on NFкB activity [28]. DCPA treatment 
resulted in a potentiation of early LPS-induced NFкB activation and could be a tool to 
probe the fundamental aspects of NFкB signaling. However, the mechanism of DCPA 
modulating NFкB is still not clear. Our current research aims to expand this model to 
incorporate mechanisms by which NFкB is regulated in macrophages. Furthermore, an 
empirical Bayesian approach will be used to establish confidence in model parameters 
and the special aspects affected by DCPA treatment. 
1.2 Regulation of NFкB activity 
Many different proteins have been identified having ability to regulate NFкB activity. 
Besides those proteins in the signaling process indentified as inhibitors of NFкB, a lot of 
other compounds like small molecules are found to modulate NFкB activity [25,26,29]. 
DCPA has also been shown to alter NFкB activity [28]. Yet, how these proteins and 
compounds regulate NFкB is still unclear [7, 8]. Moreover, the regulatory mechanisms 
may be different in different cell types. In Figure 1 which is summarized Klinke [28], we 
can see that NFкB is activated more rapidly in macrophages than in Fibroblasts following 
LPS stimulations.[28] The different dynamics of NFкB activity may be caused by 
different signaling pathways. Different cells have different functions in the immune 
system. Macrophages are important and essential to the regulation of immune response 
and the development of inflammation. Therefore, it is meaningful to Figure out the 
mechanism of NFкB activity in macrophages. 
 IкB proteins is a family of similar proteins, including IкBα, IкBβ and IкBε that has been 
identified as major inhibitors of NFкB activity in different kinds of cells [5,7]. IкBα, 
IкBβ and IкBε proteins have several structural motifs in common, including six ankyrin 
repeats and N-terminal regulatory regions (shown as Figure 2). The similarity in structure 
also correlates to similar functions: they bind to NFкB,  and mask the nuclear localization 





(IKK) liberates NFкB [9]. The slight differences in structure lead to differential functions 
or mechanisms in regulating NFкB [10, 11, 34]. For instance, different dynamics of 
NFкB activity in embryonic fibroblasts were observed in α-/-β-/- cells, α-/-ε-/- cells, and 
β-/-ε-/- cells [11]. Mathematical models have been used to explain the discrete functions 
of IкBα, IкBβ and IкBε proteins in regulation NFкB via negative feedbacks. IкBα 
proteins are rapidly synthesized in response to NFкB and are suggested to provide strong 
negative feedback leading to oscillations in NFкB activity. In contrast, IкBβ and IкBε 
proteins dampen the long-term oscillatory activity of NFкB. Sparked by this work, 
several other models has been built to help understanding the mechanism of different 













Figure 1 The dynamic activation of NF-κB in macrophages compared against 
prior studies using fibroblasts. Nuclear NF-κB was assayed by EMSA at the 
indicated times after persistent stimulation with 1 μg/ml LPS in macrophages (in 
Klinke 2008, n = 8, values reported as average ± 95% confidence interval), 0.5 
μg/ml LPS in fibroblasts demonstrated by Covert et al. (30) (○), and 0.1 μg/ml 















Besides IкBα, IкBβ and IкBε proteins, A20 is suggested as an important inhibitor of 
NFкB activation by deactivating IKK [13] or by blocking the upstream activator of IKK 
[14]. Prolonged NFкB activity was observed not only in A20-deficient fibroblasts 
following TNF stimulation [15] but also in macrophages following LPS stimulation [16]. 
Persistent phosphorylation of IкBα proteins in A20-deficient cells following the 
stimulation suggests that prolonged IKK activity results in persistent NFкB activity.  
Although A20 is essential in regulating NFкB activity following extracellular stimuli, the 
molecular mechanism of this regulation is still unknown. Ubiquitination (or 
ubiquitylation) refers to the post-translational modification of a protein by the covalent 
attachment (via an isopeptide bond) of one or more ubiquitin monomers. A20 has both 
de-ubiquitination and ubiquitin ligase domains which label proteins for proteasomal 
degradation. Wert and coworkers established receptor interacting protein (RIP) as an A20 
substrate by analyzing possible ubiquitination in the TNF-induced NFкB signaling 
pathway and found that A20 directly ubiquitinated RIP, which is essential for TNF-
induced signaling [17]. 
Figure 2 The IκB family. Schematic diagram showing different IκB proteins that 
contain several ankyrin repeats (ANK). Phosphorylation and ubiquitination at 
specific amino acid residues are indicated. Proline (P), glutamic acid (E), serine 






The expression of most of these important regulators of NFкB is also regulated by NFкB 
activity [18]. For instance, NFкB directly promotes IкBα transcription [19]. NFкB 
binding with IкBα results in a slower bound IкBα degradation rate compared to free IкBα 
[20, 21], but increases phosphorylation of IкBα by IKK [22]. Thereby, NFкB is not only 
responsible for the production but also stability of IкBα. For IкBβ and IкBε, less is 
known about their regulation by NFкB. Kearns and coworkers studied the gene 
expression of IкBα, IкBβ and IкBε in wild-type murine embryonic fibroblasts (MEFs) 
and NFкB-deficient MEFs following TNF stimulation [23]. Gene expression of IкBα, 
IкBβ and IкBε was observed increasing in wild-type cells following the stimulation, but 
not in NFкB-deficient cells. Therefore, NFкB is essential for all of IкBα, IкBβ and IкBε 
gene expression in MEFs following TNF stimulation. However, the dynamics of 
expression in response to NFкB for these species are different. In particular, IкBβ and 
IкBε had a 45 minutes transcription delay comparing to IкBα in wild-type MEFs 
following TNF stimulation [23]. Although some intermediate transcription factors, like 
Foxj1, which was demonstrated to have the ability to regulate IкBβ by Lin [24], may 
cause the time delay, the mechanisms of these different promotions by NFкB are still 
unknown. Similar to IкBα, rapid A20 gene expression was observed following NFкB 
activation in wild-type MEFs and also in bone marrow-derived macrophages (BMDMs) 
[15, 16]. NFкB controls gene expression of its inhibitors which forms auto-regulatory 
feedback loops to terminate the NFкB response. 
As illustrated by the regulation of A20 and IкBs on NFкB, these auto-feedback loops 
play different roles in regulating NFкB dynamics. Given the reciprocal nature of 
NFкB/IкB regulation, mathematical models integrated with biochemical studies have 
been an instrumental tool to understand the regulation of NFкB [31]. Most of the models 
focused on TNF-induced or LPS-induced NFкB activity in MEFs [13, 23, 30]. Biological 
events were assembled into a biochemical reaction network and modeled using non-linear 
ordinary differential equations. Parameters were refit to reproduce experimental data 
under different conditions and assumptions [12], as shown in Figure 3. Figure 3-A 





long TNF stimulation, while Figure 3-C reproduced that after 15 min-long TNF 
stimulation. Through this mathematical model which could reproduce some  
  
[B] Schematic depiction 
Figure 3 Schematic depiction of Lipniack’s model (B) and Model predictions 
versus Hoffmann et al. (2002) measurements on wild-type cells (down) (A) NF-
kB during persistent 6 h-long TNF stimulation [13]; (C) NF-kB at and after 15 






experimental data measured under different conditions, the mechanism of NFкB 
regulation by A20 and IкBα was proposed that A20 regulates NFкB activity through 
inhibiting IKK activity while IкBα through binding with NFкB and keeping it in the 
cytoplasm. Through mathematical modeling, the distinct function of other inhibitors in 
controlling NFкB activity was also demonstrated [23, 32]. 
1.3 Mathematical modeling 
Mathematical modeling has been demonstrated as an instrumental tool in understanding 
signaling mechanisms in biological system [11-13]. Common modeling approaches give 
the maximum likelihood estimate of some unknown parameters by comparing the 
simulation results and experimental data[11,13, 45]. However, in biological systems, a 
signaling network involves tens of or even hundreds of biological events like protein-
protein interaction, mRNA transcription and translation. Not all of these events are 
currently measurable. Most of the time, only some of the parameters associated with 
certain events can be measured. For other parameters, a slight change in value may not 
influence the production or affect system results in ways that are difficult to separate 
from other parameters. These parameters are called unidentifiable or inestimable. Like 
experimental studies, we need to establish a level of confidence associate with how well 
the mathematical model describes a system. 
1.3.1 Values for Parameter Identification 
Parameters associated with biological events can be measured directly by experiment or 
estimated by analysis data using a mathematical method. For parameters that can’t be 
measured currently, A priori identifiability approach was developed by Jacquez [52]. A 
priori identifiability is used to check whether the values of the parameters at a point in 
parameter space can be estimated independently for models described by systems of 
ordinary differential equations. Klinke [28] used the approach to demonstrate that 
estimates of the strength parameter of effect DCPA on NFкB activation could be 
uniquely determined from the data. The sensitivity function is defined as  





where yj represents model variables, ki denotes model parameters around a local optimum, 
and the partial derivative values are scaled by the parameter value and the maximum 
value of the model variable during the simulation. The sensitivity function is practically 
approximated by obtaining the sensitivity measure Sij at a set of dicrete time points, tk, 
and experimental conditions, [Cn]n. Then a reduced sensitivity matrix (M) is constructed 
as 
M = [Sij (t1, Cn0), ..., Sij (tk, Cn0),…, Sij (t1, Cnn), …, Sij (tk, Cnn)]
T 
                 (2) 
A set of correlation coefficients between model parameters is calculated from M. 
Parameters that are locally identifiable have correlations with all other parameters 
between in practical -0.99 and +0.99. Parameters that are not locally identifiable, termed 
a proiori unidentifiable, have correlations of greater than 0.95 and less than -0.95 with at 
least one other parameter.   
1.3.2 Simulated Annealing  
Simulated Annealing (SA) is a random searching technique, developed in 1983 to deal 
with highly nonlinear problems. The principle and advantages of SA was reviewed by 
Busetti[56]. SA exploits an analogy between the way in which a metal cools and freezes 
into a minimum energy crystalline structure (the annealing process) and the search for a 
minimum in a more general system. The principle of SA approaching the global 
maximization is similarly to using a bouncing ball which can bounce over mountains 
from valley to valley. At the beginning, it starts from a “high temperature” bounce with 
high energy to access any valley, and then finally get into a small range of valleys. The 
SA method needs a generating distribution that generates possible valleys or states to be 
explored and an acceptance distribution which depends on the difference between the 
function value of the present generated valley to be explored and the last saved lowest 
valley. The acceptance distribution decides probabilistically whether to stay in a new 
lower valley or to bounce out of it. All generating and acceptance distributions depend on 









The major advantage SA over other methods is an ability to avoid becoming trapped in 
local minima. It is flexible and able to approach global optimality. Carefully controlling 
the rate of cooling of the temperature, SA can find the global optimum. However, this 





requires infinite time. Also, the evaluation of the problem functions is essentially a “black 
box” operation as far as the optimization algorithm is concerned, because the SA 
algorithm does not require or deduce derivative information. However, for many 
applications, the computational efficiency is important. The standard implementation of 
SA algorithm is one in which a collection Markov chain of finite length are generated at 
decreasing temperatures. 
1.3.3 Markov Chain Monte Carlo Methods 
A Markov chain is a mathematical tool for statistical modeling in modern applied 
mathematics. In a Markov chain, the next state depends only on the current state, with the 
state changing randomly between steps. After sufficient amount of steps, the chain may 
reach a stationary distribution where the probability values are independent of the actual 
starting value. Since the system changes randomly, it is generally impossible to predict 
the exact state of the system in the future. However, the statistical properties of the 
system’s future can be predicted. In many applications, these statistical properties are 
important. 
Markov chain Monte Carlo (MCMC) methods are a class of algorithms for empirically 
creating a probability distribution by constructing a Markov chain that has the desired 
distribution as its equilibrium distribution. MCMC techniques provide random walks in 
parameter space whereby successive steps are weighted by the likelihood of observing 
data given the corresponding parameter values. They are widely used in the field of 
Bayesian statistics where they provide an attractive option for assessing the uncertainty in 
the model parameters given the calibration data.[51,53] One of the big challenge in the 
application of Bayesian approach to more realistic problems, such as modeling biological 
system networks, is computational efficiency. The computational efficiency of a MCMC 
algorithm depends highly on the structure of the proposal distribution. One recent 
advance in MCMC algorithms has been to improve the computational efficiency by 
dynamically adjusting the proposal distribution from a non-informative prior distribution 
at the start of the simulation to a proposal distribution that reflects the structure in the 





and applied an empirical Bayesian approach to establish the confidence that one 
particular mathematical model can describe signal transduction mechanisms in biological 
signaling networks, given the available data [37].  In the study, an Adaptive Markov 
Chain Monte Carlo (MCMC) techniques was used to assess the uncertainty in the model 
parameters given the calibration data for the mathematical model by providing random 
walks in parameter space whereby successive steps are weighted by the likelihood of 
observing data given the corresponding parameter values. Bayesian approach has been 
used to infer confidence of models for transcription factor activity and cellular signaling 
networks. Monte Carlo integration was used to approximate posterior distribution 
required for a Bayesian analysis. A Markov chain was generated, using the previous 
sample values to randomly generate the next sample.  Metropolis-Hasting algorithm can 
be used to generate a Markov chain by random sampling. Typically the first 100000 to 
500000 elements are in the burn-in or “learning” period. A poor choice of staring values 
can greatly increase the required burn-in time. The values obtained by simulated 
annealing were used as a starting point to generate Markov chains. 
Sequential steps in a generated Markov Chain exhibit autocorrelation. To minimize the 
effect of autocorrelation, a technique called “thinning” was used by selecting values from 
the Markov Chain at every nth iteration [37]. Recursive calculation of the proposal 
covariance of the Markov Chain during the MCMC run is improved by thinning. The 
expected value for some property of a model can be calculated from the following 
integral: 
   (3) 
where f(Θ) is a generic function of the model parameters. In this case f(Θ) is a 
deterministic function that provides a prediction of the dynamic trajectory of the system 
in response to a stimuli, given a set of parameter values. This equation used in 
conjunction with the posterior distribution in the model parameter provides an estimate of 





The expected value is dependent on the particular formulation of the model, M, and the 
data used in calibrating the model, Y. As not all combinations of parameters provide 
realistic simulations, values for f (Θ) are weighted by distribution of parameters given M 
and Y (i.e., the posterior distribution P (Θ|M, Y)). A Bayesian estimate of P (Θ|M, Y)) 
could be provided by computer-intensive methods like Monte Carlo algorithms. Markov 
chain represents a random walk within parameter space. Recently developed AMCMC 
can dynamically adjust the structure of the proposal distribution based upon the prior 
steps of an evolving Markov chain. The prior distribution used in this study was the same 
for all parameters, proper, normally distributed, and used to specify the initial proposal 
distribution. Following a specified “learning” period, the proposal distribution was 
adjusted to reflect the structure in the cumulative Markov chain.  
However, deciding when the cumulative Markov chain is a representative sample drawn 
from the underlying stationary distribution is still a big challenge with implementing a 
MCMC approach for Bayesian inference. Convergence is a criteria used to evaluate how 
long of a chain is necessary to traverse a representative sample of parameter space. Most 
of algorithms developed diagnose the convergence of a Markov chain by focusing on the 
model parameters. Klinke instead focused on the the predictions of the model to assess 
convergence of Markov chains using Gelman-Rubin method. The Gelman-Rubin method 
is based upon the concept that convergence has been achieved when the variance among 













2.1 Experimental Aspects 
All biological experiments were done by Irina V. Ustyugova who was a graduate 
student in John Barnet’s lab, Department of Microbiology, Immunology & Cell 
Biology, West Virginia University, Morgantown, WV, USA 
Cell culture, stimulation and DCPA treatment  The murine peritoneal macrophage cell 
line, IC-21, was cultured to 80% confluency in complete RPMI (cRPMI) Cells were 
treated with 99% pure DCPA and simultaneously stimulated with 1 g/ml LPS phenol 
extracted for various times.  100 M of DCPA were dissolved in 100% ethanol and 
added to cells.  The final ethanol concentration added to all cultures was 0.1%; control 
cultures received equal concentrations of ethanol. 
Nuclear Extracts  
Cells were then treated with either 0.1% ethanol or 100 M DCPA, then stimulated with 
1 g/ml LPS.  Cells were washed. A total protein concentration for nuclear extracts was 
determined with Coomassie Plus Protein Assay Reagent, as described by manufacturer 
(Pierce, Rockford, IL).  
Electrophoretic mobility shift assay (EMSA)  
 NF-κB consensus oligonucleotides were labeled with -32P-ATP using Ready-To-
GoTM T4 polynucleotide kinase kit. Nuclear extracts, 5 g per sample, were incubated 
with 50,000 cpm of labeled probe and 1 g/ml dI:dC to allow formation of  band shift 
complexes and electrophoresed.  The EMSA experimental results are reported as the ratio 
of the intensity measured for a particular condition (i.e. time > 0) relative to the intensity 





Western Blotting of IкBα and IкBβ  
After the nuclear extracts, IC-21 cells were treated as indicated, collected by 
centrifugation, and washed two times with cold phosphate-buffered saline. Western blot 
analysis was performed using the indicated antibodies of IкBα and IкBβ. 
2.2 Mathematical Modeling Aspects 
The application of mathematical models to describe NFкB-IкBs signaling mechanism 
was pioneered by Hoffmann A [11], and extended by many others [13, 23]. This model 
builds upon prior modeling studies by Lipniacki [13] but incorporates two key changes.  
First, the reactions were grouped into reaction classes that are defined based upon peptide 
motif-motif interactions [35]. Equal parameters are assigned to reactions in the same 
class. Additional effect factors to some complexes reactions in the presence of NFкB are 
considered, according published experimental data [36].  Second, dynamic equilibrium is 
considered between protein-protein interactions. NFкB is considered as a single protein. 
The interaction between IKK and IкBα as well as IкBαNFкB complex in the cytoplasm 
effectively proceeded as a single enzymatic degradation reaction scheme: 
                                                 E + S → ES → E 
where E is the enzyme, IKKa (IKK in active status), S is the substrate (IкBα or 
IкBαNFкB) and ES is the enzyme-substrate complex (IKKaIкBα or IKKaIкBαNFкB 
complex). Three parameters are used to describe this process, including association rate, 
a2, dissociation rate, d2 and catalytic rate, kcat. After this enzymatic process, IKKa is 
regained but IкBα is lost while NFкB is released. The interaction between IкBα and 
NFкB also consists in the forward and reverse reactions with rate a1 and d1. Dynamics of 
IKK is represented as a module, where details of upstream signaling interaction are not 
represented in detail. The description of all reactions is shown in supplement material 1. 
2.3 Model Calibration 
The reactions between all components associated with parameters were converted to a set 





them are from literature published before, while a subset of parameters will be 
determined from the experimental data. As many of the parameters are correlated, a 
parameter identifiablity analysis described by Klinke [28] was used to establish the 
parameters which can be uniquely determined, given unlimited information about the 
model. Parameters that are not locally identifiable, termed a priori unidentifiable, have 
correlation values less than -0.985 or greater than 0.985 with at least one other parameter.  
Two models were built. Model 1 was built to describe the system by fitting experimental 
data from IкBα and NFкB measured in IC-21 cells with and without DCPA treatment 
following LPS stimulation. To further study the signaling mechanism, model 2 was built 
to include also fitting IкBβ experimental data. Initial concentrations of the components 
are needed to simulate the response. The initial concentration of NFкB is assumed as 0.06 
μM in the cytoplasm [36]. All of NFкB is assumed to exist as IкBαNFкB for model 1 in 
the cytoplasm. For model 2, the initial concentration of NFкB is assumed as 0.03 μM 
кBαNFкB and 0.03 μM IкBβNFкB in the cytoplasm; the initial concentration of NFX is 
assumed as 0.02 μM in the cytoplasm. All other components are assumed as zero. A 2000 
minute period is simulated to get the equilibrium concentrations of all the variables 
before the stimulation and DCPA treatment.  
Unknown parameters obtained from the first model were used as a starting point to 
simulate the second model. Experimental data of NFкB in the nucleus, IкBα in the 
cytoplasm and IкBβ in the cytoplasm, measured previously in our lab, were used to 
calibrate the model. More unknown parameters were identified by the simulated 
annealing program. Simulated annealing is a robust and general technique to deal with 
highly nonlinear models. The greatest advantage of this technique is the ability to 
approach global optimality. The model equations are encoded and evaluated in MATLAB 
V7.1 (The MathWorks, Natick, MA). Summed squared error between experimental data 
measured previously in our lab and simulated measurements was used to determine 
goodness-of-fit. The optimum values obtained from the simulated annealing were used as 





2.4 Bayesian Approach 
After parameter identifiablity analysis, Simulated Annealing was used to find the 
optimum fitness of the given experimental data for of NFкB in the nucleus and IкBα in 
the cytoplasm. Metropolis-Hasting algorithm was used to generate possible states to be 
explored in the parameter space. An acceptance distribution depends on the difference 
between the function value of the present state to be explored and the last saved lowest 
state. The acceptance distribution decides probability whether to stay in a new state or to 
bounce out of it. The Simulated annealing program was used to produce the initial values 
for the AMCMC algorithm, shown as Figure 5. 
Using the results from Simulated Annealing program as the start point to generate a 
Markov chain by An empirical Bayesian approach using Adaptive Markov Chain Monet 
Carlo (AMCMC) algorithms, as described by Klinke [37]. The generated Chain by 
Metropolis-Hasting algorithm is autocorrelative. To minimize the effect of 
autocorrelation, a technique called “thinning” was used by selecting values from the 
Markov Chain at every nth iteration. Recursive calculation of the proposal covariance of 
the Markov Chain during the MCMC run was improved by thinning. The thinning value 
used to estimate the covariance recursively from the evolving Markov chain is 40. To 
obtain P(Θ|Y,M) from the final Markov chains, a thinning value of 20 was used. 
The prior distribution used in this study was the same for all parameters, proper, normally 
distributed, and used to specify the initial proposal distribution. Following a specified 
“learning” period, the proposal distribution was adjusted to reflect the structure in the 
cumulative Markov chain. How a Monte Carlo Markov chain is generated is as same as 
description by Klinke [37]. The Gelman-Rubin method is then used to analyze the 
convergence of the model using two parallel chains. The first N steps, called “learning 
period” or “burn-in period”, are discarded as they are assumed to be drawn from tails of 
the stationary distributions. The remainder of the parallel chains was used to estimate the 
convergence of the predictions to a stationary distribution. Two parallel Markov chains 





approximately 500 hours on a single core of a 2.66 GHz Dual-Core Intel Xeon 64-bit 
processor with 8 GB RAM.  
 
Figure 5 The AMCMC algorithm structure for our model 
The parameter values obtained using simulated annealing provided the starting point for 
these chains.  A “learning” (a.k.a. “burn-in”) period of 250,000 steps was specified a 
priori to provide an initial estimate for the proposal covariance. 
To estimate convergence, the prediction PYij obtained from a single draw from J parallel 
MCMC samples of length N, where j  N and i N. The overall variance of prediction, 
Var(PY), derived from the target distribution is estimated from the between-sequence (B) 
and the within-sequence (W) variances. The Gelman-Rubin Method diagnoses 





R = Var(PY) / W 






RESULTS AND DISCUSSION 
3.1 Analysis of the experimental data  









The changes of NFкB concentration in the nucleus of  IC-21 macrophages were 
measured following LPS stimulation or LPS stimulation and DCPA treatment for period 
of 6 hours using electrophoretic mobility shift assay, shown as in Figure 6 (A). The 
Figure 6 Initial experimental results. (A) NFкB in the nucleus measured by 
Electrophoretic mobility Shift Assay (EMSA); (B) IкBα, IкBβ and β-actin which 
was used to normalize IкBα and IкBβ, in the cytoplasm measured by western 





concentration change of IкBα and IкBβ proteins in the cytoplasm of IC-21 cells were also 
measured by western blot, shown as B in Figure 6. Ethanol treatment following LPS 
stimulation was used as control experiments. 100 µL DCPA was used to test the effect of 
DCPA on NFкB activity in macrophages. 
Differential dynamics of IкBα and IкBβ were observed following LPS stimulation for 
both ethanol and DCPA treated IC-21 cells. From Figure 6, we can see that following 
LPS stimulation with or without DCPA treatment (both of LPS and DCPA or ethanol 
were added at time 0), IкBα (middle band) concentration decreased and then rebounded 
more rapid than IкBβ (top band). All these experimental data are numerically 
summarized as Figure 7.  From Figure 7, we can see clearly that the increase of free 
nuclear NFкB concentration starts after 5 minutes, which is following the decrease in 
IкBα. The cytoplasmic IкBα reaches the lowest concentration earlier than free nuclear 
NFкB reaches its highest concentration. Following free nuclear NFкB, which is thought 
to be the active form with the ability to promote the productions of other proteins, 
cytoplasmic IкBα concentration recovers to a level close to that before the LPS 
stimulation. Following the resynthesis of cytoplasmic IкBα, the active NFкB 
concentration decreases. Whether the cells were treated with or without DCPA, the 
nuclear NFкB concentration shows oscillation and reaches a high level of constant 
activity after about 3 hours. This higher level of NFкB activity is about 8 times as that 
before the stimulation. This oscillation behavior of nuclear NFкB was also observed by 
other groups in other kind of cells.[10,11,15,18] Hoffman’s study demonstrates that, in 
fibroblasts, the negative feedback effect of IкBα on the NFкB activity signaling network 
cause the oscillation while IкBβ and IкBε dampen the oscillations and stabilize NFкB 
during longer stimulations.[11]  
We also measured cytoplasmic IкBβ concentration following LPS stimulation in IC-21 
cells shown in Figure 7 C. Unlike IкBα, the decrease of IкBβ concentration following 
LPS stimulation is much slower. After about 90 minutes following the stimulation, the 
concentration of IкBβ begins to rise, at a rate that is much slower than the rising of IкBα 






























































Figure 7 Summary of experimental data and normalized by the concentration 
before LPS stimulation (A) Nuclear NFкB (NFкBn); (B) Cytoplasm IкBα; (C) 
Cytoplasm IкBβ. Red squares represent experimental results with DCPA 






stimulation, while IкBα and the active NFкB concentration oscillate slightly around the 
constant level.  Active NFкB in the nucleus induces IкBα and IкBβ transcription. Re-
synthesized IкBα proteins bind to free NFкB in the cytoplasm to keep it in the cytoplasm. 
Re-synthesized IкBα proteins can also go to the nucleus to export free NFкB to the 
cytoplasm.[11,19] The negative feedback effect of IкBα causes the oscillation of NFкB 
activity. IкBα and IкBβ have distinct functions in regulating NFкB activity. [10] 
However, the mechanisms of IкBα and IкBβ regulation and how they regulate NFкB 
activity are still not clear. 
The different dynamic profiles of IкBα and IкBβ following an external stimulation were 
also observed by other groups.[10,11,23] According to Kearns’s study,[23] NFкB is 
essential both for IкBα and IкBβ mRNA transcription. In the wild-type cells, the IкBβ 
mRNA level remains constant for about 45 minutes after chronic TNFα stimulation, 
while IкBα mRNA level rises immediately. This is consistent with our observations on 
IкBβ protein level in the cytoplasm. We observed a 60 minute delay in resynthesis 
compared with IкBα following the LPS stimulation.  
The profile of nuclear NFкB in the cells exposed to DCPA looks similar but a little ahead 
of time compared to cells without DCPA treatment. In [28], it was demonstrated that 
DCPA has the ability to potentiate an early NFкB activity. Moreover, Klinke and 
coworkers demonstrate that an EMSA assay lacks the sensitivity to detect change in early 
NFкB activity. However, how the DCPA affects NFкB activity is still unknown.[27] Not 
surprisingly our EMSA results suggest that free NFкB concentration was not 
significantly decreased by DCPA treatment following LPS stimulation. As shown in 
Figure 7 B, IкBα concentration decreased quickly following the stimulation and increased 
immediately after NFкB activated. Differences in IкBα expression upon DCPA treatment 
do not become apparent until 3 hours following LPS stimulation. But in the first three 
hours of the LPS stimulation and DCPA treatment, the decrease is not that obvious. 
Compared with IкBα, IкBβ concentration decreased relatively slowly and following a 
delay, increased more slowly, shown as Figure 7 C. After 6 hours’ stimulation, IкBβ 
concentration in the cytoplasm increased to a level greater than before the stimulation. 





minute delay was observed in cytoplasmic IкBβ protein level following NFкB activity. 
From the western blot image, two form of IкBβ with different dynamics can be 
recognized, as shown in Figure 6 B, but are summed together as the total cytoplasmic 
IкBβ. Furthermore, DCPA treatment also decreased cytoplasmic IкBβ concentration 
following LPS stimulation. The significant decrease by DCPA treatment started from 90 
minutes, a little earlier than IкBα. We also noticed that the resynthesis of cytoplasmic 
IкBβ concentration starts at 90 minutes following the LPS stimulation with or without 
DCPA treatment and is about 60 minutes later than cytoplasmic IкBα concentration 
resynthesis. The slower decrease and delayed resynthesis of cytoplasmic IкBβ suggest 
that the contribution of this negative feedback mechanism is not a major contributor to 
the observed dynamics of NFкB activation during the first 90 minutes following LPS 
stimulation. In the first 90 minutes, IкBα appeared to be more important in regulating 
NFкB activity than IкBβ at the beginning. Therefore, in IC-21 cells, IкBα protein is a key 
early regulator of NFкB activity. However, the mechanism of how IкBα regulating NFкB 
is still unclear. To help understand the process, we developed a mathematical model to 
describe the first 90 minutes following extracellular stimulation. IкBα is more important 
as a negative feedback to regulate NFкB activity at the beginning period following LPS 
stimulation. Therefore, our initial effort to expand the mathematical model of NFкB 
activity in IC-21 cells included the contribution of IкBα alone. Using this model we 
focused on the dynamics of NFкB and IкBα in the first 90 minutes with and without 
DCPA treatment and used the model to predict the rest of the stimulation time (Model 1). 
IкBα was used to represent the functions of inhibition of NFкB activity.  We also 
compared the difference of the two sets of parameter values that fit experimental data of 
NFкB and IкBα to identify difference induced by DCPA treatment. Finally we extended 
the model to incorporate both IкBα and IкBβ and their distinct functions and dynamics. 
As suggested experimentally, IкBβ starts to play an important role on regulating NFкB 





3.2 Model topology 
3.2.1 Mathematical Models development 
Following from experimental observation, the IкBβ resynthesis occurred after 90 minutes 
following LPS stimulation; therefore, we built two models. 
 Model 1  
The first model was developed based on the simple model published by Klinke[28], but 
more proteins and mRNAs were added to describe the signaling network of NFкB 
activity.  In model 1, we focused on the first 90 minutes following LPS stimulation and 
postulate that IкBα represents the major regulator of IкB proteins at this period; for 
model 2, we included both IкBβ and IкBα as regulatory elements for NFкB.  The 
schematic diagram of model 1 is shown in Figure 8. Activation of NFкB following LPS 
stimulation of the cells is depicted as a binary on/off stimulus. Before the stimulation, the 
activity of TLR4 is set to zero (off). During the whole LPS simulation period, TLR4 is 
kept as 1. Following the stimulation, LPS binding to TLR4 activates the signaling 
network, transferring IKK from a neutral form, IKKn, to the active form, IKKa.  Active 
IKK phosphorylates free IкBα, bound IкBα, and IкBβ. The presence of NFкB makes the 
phosphorylation more efficient.[21] Free NFкB dynamically shuttles between the 
cytoplasm and the nucleus; within the nucleus, free NFкB binds to DNA, promoting the 
transcription and translation of numerous proteins including IкBα, IкBβ and A20. Newly 
synthesized IкBα goes to the cytoplasm, binding to NFкB to prevent its nuclear 
localization or shuttles to the nucleus to inhibit its binding to DNA and exporting it out of 
the nucleus.  Newly synthesized A20 inhibits IKK activity.  
The first model consists of 14 components, as listed in Table A.1 in APPENDIX: three 
status of IKK including IKKn(neutral), IKKa(active), IKKi(inactive), NFкB, IкBα, A20 
and their complexes, IKKaIкBα, IкBαNFкB, IKKaIкBαNFкB, IкBαn, IкBαnNFкBn and 
NFкBn, ( n means in the nucleus), and the following mRNAs: IкBαm and A20m(m 
denotes mRNA). IKKn(neutral) can be activated to IKKa(active), or deactivated to 





25 groups of reactions listed in Table A.2 in APPENDIX; and concentration changes of 
these components are calculated using differential equations as shown in Table A.3 in the 
APPENDIX. 
Model 2  
Based on the first model, the second model including the regulation of IкBβ was built to 
capture experimental data in the whole stimulation period. Since less is known about 
IкBβ, most of its properties are assumed based on IкBα. But one major difference with 
IкBα is proposed. The delay in IкBβ mRNA synthesis was due to an unknown 
intermediate transcription factor (NFX), whose synthesis was dependent on NFкB 
activation.  Therefore, we assume that NFX can shuttle between the nucleus and the 
cytoplasm. NFX is NFкB inducible and promotes the transcription and translation of 
IкBβ responsible. The schematic demonstration of the second model is shown in Figure 9. 
Before the stimulation, IкBβ exists in the cytoplasm and similar to IкBα is bond to NFкB. 
Active IKK phosphorylates IкBβ to release NFкB. In contrast to IкBα and, IкBβ is 
induced through an intermediate nuclear factor NFX. New synthesized IкBβ proteins 
enter the cytoplasm, binding with free NFкB to inhibit its activity. In this model, we 
assume that IкBβNFкB can shuttle between the cytoplasm and the nucleus, while IкBβ 
could shuttle between the cytoplasm and the nucleus, and bind to nucleus NFкB and 
promote the export of this complex from the nucleus. 
After classifying biochemical reactions, 46 groups of reactions are converted to describe 
the concentration change of 24 components, as shown in table 1 and 2. Differential 
equations being used to describe the rates of change of the concentrations of these 
components are shown in Table A.4 in APPENDIX. 
For the big model, because of too many unknown parameters and most of them may be 
correlated, the simulation annealing program couldn’t get a good fit for all the three data 
sets, free NFкB, IкBα and IкBβ. Otherwise, more steps are needed to get the best fit 






Figure 8 Schematic demonstration of the model 1for NFкB signaling following the LPS 
stimulation. A schematic diagram of the biochemical events represented in the 
mathematical model represented using Cell Designer 4.1. The model represents 
synthesis of IкBα and A20, association and dissociation between IкBα + IKKa, IкBα + 
NFкB, and IKKa + IкBα + NFкB, and the degradations of IKK, IкBα and A20 proteins, 
and IкBα and A20 mRNAs, and transcriptions of IкBα and A20 mRNAs and 










Figure 9 Schematic demonstration of the model 2 for NFкB signaling. Besides IкBα 
as an inhibitor to NFкB, IкBβ was added to the signaling network. The interactions 
between IкBβ, NFкB, and IKKa were added into the model 1. Further, an unknown 
nuclear factor NFX was proposed to promote IкBβ mRNA transcription. The 
synthesis, degradation and transportation of NFX were also included in the diagram 





3.2.2 Model Calibration 
The mathematical models, shown schematically in Figure 6 and 7, were calibrated against 
values obtained from experimental data measured previously in our lab. The values were 
obtained with IC-21 cells (macrophage cell line) in response to 1 μg/ml LPS with 100 μM 
ethanol (as control experiment) or with 100 μM DCPA. Nucleus NFкB was measured by 
EMSA while total IкBα and IкBβ in the cytoplasm were measured by western blot. Initial 
data is shown in Figure 6, while the numerical summary is shown in Figure 7. The 
mathematical models were implemented in MATLAB as detailed in supplement 2. 
Maximum likelihood values for the parameter were determined using simulated 
annealing. The specific parameter values are shown in Table 3.2. An empirical Bayesian 
approach was used to estimate the uncertainty in the model parameters given the 
available calibration data.  
3.2.3 “A priori” identifiability analysis 
Sensitivity analysis (SA) is the study of how the variation (uncertainty) in the output of a 
mathematical model can be apportioned, qualitatively or quantitatively, to different 
sources of variation in the parameters, either rate constants or initial conditions associated 
with a model.  Based upon how the model is constructed, different parameters influence 
the output of the model in the same way. These parameters that cannot be estimated 
separately are called unidentifiable parameters. 
Correlation of the unknown parameters in model 1 was analyzed and the results are 
shown in Table 3.1. This symmetric table represents a correlation matrix where each 
element in the table represents the correlation between the two parameters in the row and 
in the column. If the absolute value greater than 0.95, we will consider these two 
parameters are nonidentifiable. From the table, we can see that some parameters are not 
correlated to any other parameters. For instance, k2 which associates with IKK 
inactivation via A20, has correlation values with other parameters all smaller than 0.95. 
Therefore, it is not correlated to any other parameters in this model and can be identified.  





instance, s1, which represents the inducible production of IкBα mRNA, and t1, which 
represents the translation rate of IкBα, are completely correlated (0.999). For instance, 
the effect of slow IкBα mRNA production on the observed cytoplasmic IкBα and nuclear 
NFкB concentration could be compensated by fast translation of IкBα mRNA to IкBα 
protein. Whether the production is slow and the translation is fast or the translation is 
slow and the production is fast will have the same effect on the observed cytoplasmic 
IкBα protein concentration. Therefore, we cannot uniquely determine s1 and t1 given the 
mathematical structure of the model. However, as we don’t have enough information 
about these parameters, we allow the simulation annealing algorithms to estimate them 
and optimize the fitness of the model to experimental data. Then AMCMC will be used to 
estimate the uncertainty in the model parameters.  
 
 





Table 3.2 Comparison of the parameter values fit to the two experimental conditions. 
There values represent the maximum likelihood values as determined using simulated 
annealing. 
Parameters Definition Without DCPA With DCPA 
s1 IκBα inducible synthesis rate  3.80e-3 2.95e-5 
cs1 IκBα constitutive synthesis rate  3.00e-12 2.57e-13 
t1 IκBα translation rate 3.00e-4 8.23e-1 
s2 A20 inducible synthesis rate 314.22 0.24 
cs2 A20 constitutive synthesis rate 3.13e-4 1.65e-11 
dm2 A20 mRNA degradation rate 28.23 0.16 
t2 A20 translation rate 3.10 0.59 
k1 IKK activation rate 0.93 2.71e-4 
k2 IKK inactivation rate by A20 0.59 0.37 
k3 IKK spontaneous inactivation rate 3.00e-7 1.33e-18 
kprod IKKn production rate 0.16 6.94e-4 
kdeg IKKa, IKKn and IKKi degradation 0.10 8.7e-4 
e1a IκBα nuclear import rate 4.48e-4 1.21e-4 
i1 IκBα nuclear export rate 3.10e-3 5.04e-4 









3.2.4 Results of Simulated Annealing 
The simulation results for model 1 are compared against the experimental data without 
DCPA are shown in Figure 10. The first 90 minutes of total IкBα in the cytoplasm and 
free NFкB in the nucleus following the LPS stimulation were used to select parameter 
values using simulated annealing. The resulting simulation is compared against the whole 
6 hours observation period in Figure 10. 
As shown in Figure 10, the simulation response was based on the first 90 minutes 
experimental data, can still predict NFкB activity well for the rest of 6 hrs after the 
stimulation. However, the model predicts higher levels of cytoplasmic IкBα data after 90 
minutes than was experimentally observed. In other words, additional inhibitors besides 
IкBα are needed to keep NFкB activity as measured.  
 
Figure 10 Simulation results for model 1 compared with experimental data without 
DCPA treatment using simulated annealing program. Line curves are the simulation 
results respectively for total IкBα in the cytoplasm and free NFкB in the nucleus. The + 
symbols are the experimental data of total cytoplasmic IкBα, while the о symbols are the 






The simulation results for the experiment with DCPA treatment is shown in Figure 11. 
The simulation results for the experimental data with DCPA treatment suggest an 
enhanced dampening of the NFкB oscillations as compared to without DCPA treatment, 
while the overall agreement between model and data is not particularly good. 
 
Figure 11 Simulation results for model 1 compared with experimental data with DCPA 
treatment by simulated annealing program. Line curves are the simulation results 
respectively for total IкBα in the cytoplasm and free NFкB in the nucleus. The + symbols 
are the experimental data of total cytoplasmic IкBα, while the о symbols are the 
experimental data of free nuclear NFкB. 
From table 3.2, we can see most of the parameter values are much different for 
experiments without DCPA and with DCPA. Except k2, e1a and e2a are in the same level, 
all other parameter are much different. It is difficult to say which parameters are changed 
by DCPA. Even values for some parameters are much different, the simulated results 
against the two experimental conditions are still in the same level. For example, the 
transcription of IкBα mRNA, s1 and the translation of IкBα rnRNA should be correlated. 
For experimental data without DCPA treatment, s1 is 3.8e-3 and t1 is 3.0e-4, while for 
experimental data with DCPA treatment, s1 is 2.947e-5 and t1 is 8.229e-1. A small 
production rate needs a big translation rate to get the similar the protein production level.  
To further decide which parameters are identifiable, a priori identifiably analysis was 





3.3 Results of AMCMC 
A series of Markov chains generated using Metropolis-Hasting algorithm were used to 
estimate the conditional uncertainty in the model parameters given the experimental data 
with and without DCPA treatment. The proposal distribution is scaled dynamically to 
achieve an acceptance fraction of 0.2. The trace of the acceptance fraction is shown as a 
function of AMCMC step, in Figure 12 (A, C). The trace of the covariance scaling factor 
is shown as a function of AMCMC step, in Figure 12 (B, D). The trace of the acceptance 
fraction demonstrates that the scaling factor was adjusted at regular intervals to maintain 
the acceptance fraction around 0.2.  
The trace of the conditional probability for each of the two chains against experimental 
data with and without DCPA treatment, shown in Figure 13, the better the fitness is, the 
greater the P(Y|Θ,M) is. From the results, chain 2 fits the results better than Chain 1. 
The Gelman-Rubin potential scale reduction factor (PSRF) was applied to the model 
predictions to access the convergence of the cumulative Markov Chains.[37] The 
Gelman-Rubin PSRF statistics were calculated for the species observed experimentally as 









Figure 12 Evolution of the performance of the AMCMC algorithm. AMCMC model fits 
for DCPA treated (panels C and D) and untreated cells (panels A and B) are shown 
separately. The proposal covariance scaling factor (B, D) and the acceptance fraction 
(A, C) are shown as a function of AMCMC step against experimental data. The results 









Figure 13 Evolution in the likelihood, P(Y|Θ,M), as a function of AMCMC step. The 
normalized likelihood value is shown as a function of AMCMC step for both two parallel 
chains against experimental data without DCPA treatment. The results for each of the two 
chains are shown in different colors: chain 1(Blue), chain 2(Red). 
The colored contours correspond to values of the PSRF. The model predictions exhibited 
a potential scale reduction factor of below 1.2 immediately after the “learning” period. 
The variability among chains, as represented by an increase in PSFR, increased as a 
function of simulation time, existed for both NFкB and IкBα. This behavior was due to 





percentile, 5th percentile, and median responses for each of the two chains are overlaid 
upon the experimental data without DCPA treatment in Figure 15. Traces for each of the 
parameters are shown in Figure 16. Density distribution for the model parameters is 
shown in Figure 17.  Covariance structure of P (Θ|Y) is shown in Figure 18. 
 
 
Figure 14 Gelman-Rubin assessment of the Convergence of AMCMC . A contour 
plot of the Gelman-Rubin statistic applied to the model predictions is shown as a 
function of time (i.e., the y-axis) and as a function of the cumulative chain up to a 
specific AMCMC step (i.e., the x-axis). Two parallel chains were used to calculate 
the Gelman-Rubin statistics for the simulated (panels A and C) Free NFкB 
expression in the nucleus and (panels B and D) total IкBα in the cytoplasm. Values 







Figure 15 The mathematical model 1 for early signaling events reproduces the early 
dynamics for activation of NFкB. Simulated results (lines) are compared against the 
experimental observations without DCPA treatment (symbols). The uncertainty in the 
model predictions obtained from each chain is represented by three lines of the same 
color: the most likely prediction is represented by the solid lines and the dashed lines 
represent the 95th and 5th percentile of the predicted response. The results for each of 
the three parallel chains are shown in different colors: chain 1 (Red), chain 2 (Blue). 
(A, C) Simulated response (lines) versus measured free NFкB (squares) in the 






In Figure 14, the Gelmn Rubin statistic suggests convergence between the two chains at 
the initial start point. At longer times the two predictions from the two chains diverge. In 
Figure 16, the trace of the parameters suggests that the accepted parameter values are 
very different for the two chains. 
The posterior distribution in the predictions (see in Figure 15) shows that even both 
chains (red and blue) reproduce most the experimental data in the first 90 min, but their 
oscillation frequencies are much different.  The blue chain fits the NFкB data better while 
the red chain fits the IкBα data better. It seems that the frequencies of these two sets of 
data are different. One chain tries to catch the frequency of one set data while the other 
tries to catch the frequency of the other one.  Even after 1 million steps, these two chains 
still can’t find a set of parameter values to fit both frequencies. According to Hyyot’s 
work[54] and Nelson’s study[55], the external stimulations can cause the frequency of 
NFкB to vary a lot. Because NFкB and IкBα were measured on different dates, a slight of 
difference of the LPS stimulation maybe cause the variance of signaling frequency. 
From the normalized error of the model prediction, shown as Figure 17, we can see that, 
the ranges of parameters in the blue chains are much bigger than those of the red one. The 
blue chain has a difficult time to find a best fitness for both of the data. This is also 
because of the correlations among parameters in the signaling network. From the 
Covariance structure of P (Θ|Y), shown as Figure 18, we can also see that most of the 







Figure 16 AMCMC summary plots for each of the model parameters for model 1 
without DCPA treatment. The trace of each of the model parameters is shown as a 
function of MCMC step. The traces for two parallel chains are shown in different 







Figure 17 Normalized Distributions in Parameters for model 1 without DCPA treatment. 
The distribution in the sum of the normalized error between the calibration data and the 
model predictions is shown for each study used in the analysis.  Distribution for the two 
parallel chains against experimental data without DCPA treatment is shown in different 





Figure 18 Covariance structure of P (Θ|Y) for model 1 without DCPA treatment. The 
pairwise correlation coefficients of the parameters derived from all two thinned (Kthin = 
200) Markov chains are shown above the diagonal. A high value for the correlation 
coefficient suggests that the parameters are unidentifiable given the calibration data. 
Below the diagonal, pairwise projections of the marginalized probability density for P 
(Θ|Y) are shown. The parameter names are shown on the diagonal. Each scatter plot axis 
spans a range of 1012(i.e., (log-mean-6.0 to log-mean+6.0)).The values in each scatter 
plot are centered at the log-mean values (i.e., the expectation maximum) determined from 







Figure 19 AMCMC summary plots for each of the model parameters for experimental 
data with DCPA treatment. The trace of each of the model parameters is shown as a 
function of MCMC step. The traces for two parallel chains are shown in different colors: 
chain 1 (Red) and chain 2 (Blue) 
For the experimental data with DCPA treatment, we also did MCMC sampling to 
compare with the result for experimental data with DCPA treatment. From the 
convergence plot, shown as Figure 14, we can see that some of points are converged 
while some of them are not. Combined with the prediction of the simulation results, 
shown as Figure 15, although both chains could fit most of the data points, the frequency 
vary so much that they are not converged at other time points. From that we can also 






Figure 20 Normalized Distributions in Parameters for experimental data with DCPA 
treatment. The distribution in the sum of the normalized error between the calibration 
data and the model predictions is shown for each study used in the analysis.  Distribution 
for the two parallel chains are shown in different colors: chain 1(Blue) and chain 2(Red) 
 
Using the first 90 minutes’ experimental data to estimate the values of the parameter and 
the rest of 6 hours experimental period has some limits like the oscillation frequency of 
NFкB activity and the prediction vary much. To further test the model, we applied the 
AMCMC algorithm to the data of the whole 6 hours experimental period. From the 





more consistent compared with that only using the first 90 minutes of data, shown as 
Figure 21 and Figure 22. However, even the model are more converged, but from the 
trace of all the parameters, shown as Figure 27, the parameters sampling by two chains 













Figure 21 - Convergence of AMCMC . A contour plot of the Gelman-Rubin statistic of 
the model predictions as a function of time (i.e., the y-axis) calculated as a function of 
the cumulative chain up to a specific AMCMC step (i.e., the x-axis). Two parallel 
chains were used to calculate the Gelman-Rubin statistics for the simulated Free 
NFкB(panels A, C)  expression in the nucleus and total IкBα (panels B,D) in the 
cytoplasm without and with DCPA treatment. Values less than 1.2 suggest convergence 
of the chains. The models were fit to the entire six hour time period following ;PS 






Figure 22 The mathematical model 1 for early signaling events reproduces the early 
dynamics for activation of free NFкB expression (A, C) in the nucleus and IкBα (B, D) in 
the cytoplasm. Simulated results (lines) are compared against the experimental 
observations (symbols) used to calibrate the mathematical model for the entire 6 hours 
experimental data without DCPA treatment (panels A and B) and with DCPA treatment 
(panels C and D). The uncertainty in the model predictions obtained from each chain is 
represented by three lines of the same color: the most likely prediction is represented by 
the solid lines and the dashed lines represent the 95th and 5th percentile of the predicted 
response. The results for each of the three parallel chains are shown in different colors: 






Figure 23 AMCMC summary plots for each of the model parameters for experimental 
data without DCPA treatment. The trace of each of the model parameters is shown as a 
function of MCMC step. The traces for two parallel chains are shown in different colors: 









Figure 24 The mathematical model 2 for early signaling events reproduces the early 
dynamics for activation of NFкB. Simulated results (lines) are compared against the 
experimental observations (symbols) used to calibrate the mathematical model. The 
uncertainty in the model predictions obtained from each chain is represented by three 
lines of the same color: the most likely prediction is represented by the solid lines and the 
dashed lines represent the 95th and 5th percentile of the predicted response. The results 
for each of the three parallel chains are shown in different colors: chain 1 (Red), (A) 
Simulated response (lines) versus measured free NFкB (squares) in the nucleus without 
DCPA treatment; (B) Simulated response (lines) versus measured total IкBα (squares) in 
the cytoplasm without DCPA treatment; (C) Simulated response (lines) versus measured 
total IкBβ (squares) in the cytoplasm without DCPA treatment. 
 





Combine the measured cytoplasmic IкBβ data, which re-increased after 90 minutes 
following the LPS stimulation, IкBβ should play an important role to regulate NFкB 
activity in IC-21 cells after 90 minutes following the LPS stimulation. Therefore, to 
better understand the regulation of NFкB activity in macrophages, IкBβ should be 
included into the signaling network. 
For the big model, to involve IкBβ in the signaling network, more parameters are 
introduced, which causes more calculation in the modeling progress. From our current 
MCMC prediction, we can see that the big model couldn’t catch the second peak of 
NFкB. However, it gives a good simulation of the trend of all NFкB, IкBα and IкBβ 
following LPS stimulation in macrophages. More experimental data are needed to 











4.1 Regulation of NFкB activity following LPS stimulation 
 
Macrophages play an important role in the immune system. NFкB is an essential nuclear 
transcription factor in many kinds of cells including macrophages. NFкB induces or 
promotes the productions of lots of proteins. Conversely, the activity of NFкB is also 
regulated by other proteins. From our experimental data, IкBα proteins play a major role 
in regulating NFкB activity. Our mathematical Model 1 works well by using the first 90 
minutes data to predict the rest of the 6 hours’ experiment measured free NFкB in the 
nucleus and total IкBα in the cytoplasm. Further, the stimulation results show that 
additional proteins besides IкBα are needed to keep the NFкB activity in the level as 
measured after 90 minutes following the LPS stimulation. This result is consistent with 
our experimental results which showed that IкBβ proteins are produced 90 minutes after 
LPS stimulationand eventually rise to a higher level than that before the LPS stimulation. 
Therefore, we conclude that IкBα proteins are playing a major role in regulating the 
NFкB activity in the beginning of the LPS stimulation and then IкBβ proteins become 
more important as the time increases. 
 
4.2 Mathematical Modeling of NFкB signaling network 
 
Based on our conclusion from experiment measured NFкB, IкBα and IкBβ, we 
developed two mathematical models, model 1 and model 2. In model 1, IкBα represent 
the role of inhibitors of NFкB and is also induced by NFкB. A20 is used to regulate IKK 
activity and also induced by NFкB. Two negative feedbacks involve 14 components and 
25 groups of reactions. Twenty seven parameters are associated with these reactions 





the NFкB signaling. Furthermore, more IкBα proteins are predicted than measured, 
which is consistent with the increased IкBβ proteins measured by the experiment.  Model 
2 uses an unknown nuclear factor NFX to introduce IкBβ mRNA and also cause the 
delay of IкBβ mRNA transcription, comparing with IкBα mRNA. Model 2 includes 46 
groups of reactions, translations and transportations. The simulation annealing program 
was not able to select appropriate simulate this high dimensional model. We used MCMC 
sampling to fit the model and could simulate for all NFкB, IкBα and IкBβ, as measured 
by the experiment. However, the fit was not good enough to catch most of the observed 
dynamics. More information about the parameters in the signaling network and the 
unknown nuclear factor NFX is needed to further improve Model 2. 
From the a priori identifiability analysis, some of these parameters in Model 1 are 
correlated to each other. Comparing the parameter values fitted by the simulation 
annealing program, they are much different for the experimental data without DCPA and 
with DCPA treatment. It is difficult to say whether these differences are because of the 
DCPA effect or just a result of the correlation between parameters. Similarly, we can 
expect parameters are correlated in the Model 2, too. 
 
4.3 AMCMC to estimate the conditional uncertainty in the model parameters 
 
Two parallel Markov chains generated using Metropolis-Hasting algorithm were used to 
estimate the conditional uncertainty in the model parameters against experimental data 
with and without DCPA treatment. Using data of the first 90 minutes following the LPS 
stimulation, the model doesn’t converge, although it could catch most of the data points. 
The frequency of the predicted oscillations varies a lot between different chains. This 
may be because of the frequency of the two data sets NFкB and IкBα were measured 
under slightly different conditions. Slight difference in the external stimulation by LPS 
may cause the difference of frequency of these two data sets.  
However, when we include all the data from the whole 6 hours experiments, the 
convergence of the model is improved. The predictions of the two chains for 





improved fit may be due to inclusion of additional parameters into the model. Model 
discrimination criteria should be used to compare these two models. Overall more 
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Table A.1 List of Models Variables 
Variable Name Definition Units 
TLR4 Toll-like receptor 4 1 
R0 LPS Stimulation signal - 
IKKn Free neutral cytoplasmic IKK proteins μM 
IKKn Free active cytoplasmic IKK proteins μM 
IKKn Free inactive cytoplasmic IKK proteins μM 
IkBa Free cytoplasmic IkBa proteins μM 
NFkB Free cytoplasmic NFkB  μM 
IKKaIkBa Cytoplasmic IKKa-IkBa complexes μM 
IKKaIkBaNFkB Cytoplasmic IKKa-IkBaNFkB complexes μM 
A20 Cytoplasmic A20 proteins μM 
A20m A20 mRNA μM 
IkBam IkBa mRNA μM 
IkBan Free Nuclear IkBa proteins μM 
NFkBn Free Nuclear NFkB μM 
IkBaNFkB Cytoplasmic IkBaNFkB complexes μM 
IkBanNFkBn Nuclear IkBa-NFkB complexes μM 
IkBb (#) Free cytoplasmic IkBb proteins μM 
IkBbNFkB (#) Cytoplasmic IkBbNFkB complexes μM 
IKKaIkBb (#) Cytoplasmic IKKa-IkBb complexes μM 
IKKaIkBbNFkB (#) Cytoplasmic IKKa-IkBaNFkB complexes μM 
IkBbm (#) IkBb mRNA μM 
IkBbn (#) Free Nuclear IkBb proteins μM 
IkBbnNFkBn (#) Nuclear IkBb-NFkB complexes μM 
NFX (#) Unknown transcription factor X μM 
NFXn (#) Nuclear unknown transcription factor X μM 
NFXm (#) Unknown transcription factor X mRNA μM 





Table A.2  Reaction rate equations of  Model 1 and Model 2 for NFкB signaling pathway 
Reaction                                 Rate Relationship      
Reaction class 1: IkBa-NFkB Association 
R1a = a1 * NFkB * IkBa 
R1b = a1 * NFkBn * IkBan 
R1c = a1 * NFkB * IKKaIkBa 
 
Reaction class 2: IKKa-IkBa Association 
R2a  = a2 * IKKa * IkBa 
R2b = a2 * f1 * IKKa * IkBaNFkB 
 
Reaction class 3: IkBa-NFkB  dissociation  
R3a = d1 * IkBaNFkB  
R3b = d1 * IkBanNFkBn 
R3c = d1 * IKKaIkBaNFkB 
 
Reaction class 4: IKKa-IkBa  dissociation  
R4a = d2 * IKKaIkBa 
R4b = d2 * f1 * IKKaIkBaNFkB 
 
Reaction class 5: IKKa-IkBa Catalytic dissociation 
R5a  = kcat * IKKaIkBa 
R5b  = kcat * f2 * IKKaIkBaNFkB 
 
Reaction class 6:  Degradation of  IKK 
R6a = kdeg * IKKn 
R6b = kdeg * IKKa  
R6c = kdeg * IKKi 
 





R7  = de1 * IkBa 
 
Reaction class 8: Degradation of  IkBa complex to NFkB 
R8  = de3 * IkBaNFkB 
 
Reaction class 9: Degradation of  A20 proteins 
R9  = de2 * A20 
 
Reaction class 10: Degradation of  IkBa mRNA 
R10  = dm1 * IkBam 
 
Reaction class 11: Degradation of  A20 mRNA 
R11  = dm2* A20m 
 
Reaction class 12: Synthesis of IKKn 
R12  = kprod 
 
Reaction class 13: Inducible synthesis of IkBa mRNA 
R13  = s1 *  NFkBn 
 
Reaction class 14: Inducible synthesis of A20 mRNA 
R14  = s2 *  NFkBn  
 
Reaction class 15: Constitutive synthesis of IkBa mRNA 
R15  =  cs1 
 
Reaction class 16: Constitutive synthesis of A20 mRNA 
R16  = cs2 
 
Reaction class 17: Translation from IkBa mRNA to IkBa proteins 






Reaction class 18: Translation from A20 mRNA to A20 proteins 
R18= t2 * A20m 
 
Reaction class 19: Activation of IKKn to IKKa 
R19= k1 *  R0 *  IKKn * TLR4  
 
Reaction class 20: Inactivation of IKKa because of A20 
R20 = k2 * R0* A20* IKKa 
 
Reaction class 21: Spontaneous Inactivation of IKKn to IKKi 
R21= k3 *  IKKa 
 
Reaction class 22: IkBa Import to the nucleus 
R22= i1a * IkBa 
 
Reaction class 23: IkBa export from the nucleus to cytoplasm 
R23 = e1a * IkBan 
 
Reaction class 24: IkBanNFkBn export from the nucleus to cytoplasm 
R24 = e2a * IkBanNFkBn 
 
Reaction class 25: NFkB import to the nucleus from cytoplasm 
R25 = i1 * NFkB  
 
Reaction class 26: IkBb-NFkB Association (#) 
R26a = a3 * NFkB * IkBb 
R26b = a3 * NFkB * IKKaIkBb 
R26c = a3 * NFkBn * IkBbn 
 





R27a  = a4 * IKKa * IkBb 
R27b = a4 * f3 * IKKa * IkBbNFkB 
 
Reaction class 28: IkBb-NFkB  dissociation (#) 
R28a = d3 * IkBbNFkB 
R28b = d3 * IKKaIkBbNFkB 
R28c = d3 * IkBbnNFkBn 
 
Reaction class 29: IKKa-IkBb dissociation (#) 
R29a = d4 * IKKaIkBb 
R29b = d4 * IKKaIkBbNFkB 
 
Reaction class 30: IKKa-IkBbCatalytic dissociation (#) 
R30a  = kcatb * IKKaIkBa 
R30b  = kcatb * f2 * IKKaIkBaNFkB 
 
Reaction class 31: Degradation of   free IkBb proteins (#) 
R31  = de4 * IkBb 
 
Reaction class 32: Degradation of  IkBb complex to NFkB (#) 
R32  = de5 * IkBbNFkB 
 
Reaction class 33: Degradation of  NFX mRNA (#) 
R33  = dm3 * NFXm 
 
Reaction class 34: Degradation of  IkBb mRNA (#) 
R34  = dm4* IkBbm 
 
Reaction class 35: Inducible synthesis of NFX mRNA (#) 






Reaction class 36: Inducible synthesis of IkBb mRNA (#) 
R36 = s4 *  NFXn 
 
Reaction class 37: Constitutive synthesis of NFX mRNA (#) 
R37  =  cs3 
 
Reaction class 38: Constitutive synthesis of IkBb mRNA (#) 
R38  = cs4 
 
Reaction class 39: Translation from NFX mRNA to NFX proteins (#) 
R39 = t3 * NFXm 
 
Reaction class 40: Translation from IkBb mRNA to IkBb proteins (#) 
R40= t4 * IkBbm 
 
Reaction class 41: NFX Import to the nucleus (#) 
R41= i3 * NFX 
 
Reaction class 42: NFX export from the nucleus to cytoplasm (#) 
R42 = e3 * NFXn 
 
Reaction class 43: IkBb Import to the nucleus (#) 
R43= i1b * IkBb 
 
Reaction class 44: IkBb export from the nucleus to cytoplasm (#) 
R44 = e1b * IkBbn 
 
Reaction class 45: IkBbnNFkBn export from the nucleus to cytoplasm (#) 
R45 = e2b * IkBbnNFkBn 
 





R46  = de6 * NFX 
(#) represents the components which are involved only in Model 2. 
 
Table A.3 Differential equations that define the mathematical model 1 for NFkB 
signaling pathway 
dIKKn/dt                        =  R12 - R19 - R6a 
dIKKa/dt                        =  R19 - R20 - R21- R6b - R2a - R2b + R4a + R4b + R5a + R5b 
dIKKi/dt                         =  R20 + R21 - R6c 
dIKKaIkBa/dt                =  R2a - R4a - R5a –R1c + R3c 
dIKKaIkBaNFkB/dt      =  R1c + R2b- R3c - R4b - R5b 
dNFkB/dt                       =  R3a + R3c - R1a- R1c + R5b + R8 - R25  
dNFkBn/dt                     =  R3b + kv * R25 - R1b 
dA20/dt                          =  R18 - R9 - R20 
dA20m/dt                       =  R16 + R14 -R11 
dIkBa/dt                         =  R3a -R1a + R4a -R2a -R22+R23/kv +R17-R7 
dIkBan/dt                       =  R3b - R1b +  kv * R22 - R23 
dIkBam/dt                      =  R13+ R15 - R10 
dIkBaNFkB/dt               =  R1a - R3a - R2b +R4b + R24 / kv - R8 


















Table A.4 Differential equations that define the mathematical model 2 for NFkB 
signaling pathway 
dIKKn/dt                        =  R12 - R19 - R6a 
dIKKa/dt                         =  R19 - R20 - R21- R6b - R2a - R2b + R4a + R4b + R5a    + 
R5b- R27a - R27b + R29a + R29b + R30a + R30b 
dIKKi/dt                         =  R20 + R21 - R6c 
dIKKaIkBa/dt                =  R2a - R4a - R5a –R1c + R3c 
dIKKaIkBaNFkB/dt      =  R1c + R2b- R3c - R4b - R5b 
dNFkB/dt                       =  R3a + R3c - R1a- R1c + R5b + R8 - R25 + R28a + R28b - 
R26a - R26b + R30b + R32  
dNFkBn/dt                     =  R3b + kv * R25 - R1b - R26c + R28c 
dA20/dt                          =  R18 - R9 - R20 
dA20m/dt                       =  R16 + R14 -R11 
dIkBa/dt                         =  R3a -R1a + R4a -R2a -R22+R23/kv +R17-R7 
dIkBan/dt                       =  R3b - R1b +  kv * R22 - R23 
dIkBam/dt                      =  R13+ R15 - R10 
dIkBaNFkB/dt               =  R1a - R3a - R2b +R4b + R24 / kv - R8 
dIkBanNFkBn/dt           =  R1b - R3b - R24 
dIkBb/dt                        =  R40 -R26a -R27a + R28a + R29a - R31 -R43 + R44/kv 
dIkBbNFkB/dt               =  R26a - R27b - R28a + R29b - R32+ R45/kv 
dIKKaIkBb/dt                =  R27a - R29a - R26b - R30a + R28b 
dIKKaIkBbNFkB/dt      =  R26b + R27b- R28b - R29b - R30b 
dIkBbm/dt                     =  R36+ R38 - R34 
dNFX/dt                        =  R39 - R41 + R42/kv - R46 
dNFXn/dt                      =  kv * R41 - R42 
dNFXm/dt                     = R37 + R35 - R33 
dIkBbn/dt                      = R43/kv - R44 - R26c + R28c 





Table A.5 List of parameters and corresponding values model 1 and model 2. The values 
for the reaction rate parameters correspond to the maximum likelihood values Numerical 
subscripts indicate the reaction class to which the parameters correspond. Values 
determined during model calibration are indicated by an asterisk (*).  
Symbol Definition Value Units Refs 
a1 IkBa-NFkB association rate 0.5 s
-1
 11,13 





f1 The factor of NFkB on IKKa-IkBa association  0.2 - 11,22 
kcat KKa-IkBa catalytic dissociation rate  s
-1
 * 
f2 The factor of NF-kB on IKKa-IkBa catalysis 5 - 11,22 
d1 IkBa-NFkB reversible dissociation rate 1.25e-3 s
-1
 11 
d2 IKKa-IkBa reversible dissociation rate 0.5e-3 s
-1
 11 
s1 IkBa-inducible mRNA synthesis  s
-1
 * 
s2 A20-inducible mRNA synthesis  s
-1
 * 
cs1 IkBa-constitutive mRNA synthesis  μM s
-1
 * 
cs2 A20-constitutive mRNA synthesis  μM s
-1
 * 
de1 Spontaneous, free IkBa protein degradation 0.0001 s
-1
 20 
de2 A20 protein degradation 0.0003 s
-1
 13 
de3 IkBa degradation (complexed to NF-kB) 2e-5 s
-1
 20 
dm1 IkBa mRNA degradation 0.0004 s
-1
 43 
dm2 A20 mRNA degradation  s
-1
 * 
t1 IkBa translation rate 0.5 s
-1
 13 
t2 A20 translation rate  s
-1
 * 
k1 IKK activation rate 0.0025 s
-1
 13 
k2 IKK inactivation rate by A20 0.1 s
-1
 13 
k3 IKKspontaneous inactivation rate 0.0015 s
-1
 13 
kprod IKKn production rate 2.5e-5 s
-1
 13 
kdeg IKKa, IKKn and IKKi degradation 1.25e-4 s
-1
 13 
kv Cytoplasmic to nuclear volume 7 - 45 
i1 NF-kB nuclear import rate 0.09 s
-1
 11 







e1a IkBa nuclear export rate 0.0002 s
-1
 11 
e2a IkBa-NFkB nuclear export rate 0.014 s
-1
 * 
dcpa  DCPA treatment concentration 0 or 100 μM - 
 The following parameters are only in Model 2    
a3 IkBb-NFkB association rate 0.5 s
-1
 11,13 





f3 The factor of NFkB on IKKa-IkBb association  5 - 11,22 
kcatb KKa-IkBa catalytic dissociation rate  s
-1
 * 
f4 The factor of NF-kB on IKKa-IkBb catalysis 5 - 11,22 
d3 IkBb-NFkB reversible dissociation rate 1.25e-3 s
-1
 11 
d4 IKKa-IkBb reversible dissociation rate 0.5e-3 s
-1
 11 
s3 NFX-inducible mRNA synthesis  s
-1
 * 
s4 IkBb -inducible mRNA synthesis  s
-1
 * 
cs3 NFX-constitutive mRNA synthesis  μM s
-1
 * 
cs4  IkBb-constitutive mRNA synthesis  μM s
-1
 * 
de4 Spontaneous, free IkBb protein degradation 0.0001 s
-1
 20 
de5 IkBb degradation (complexed to NF-kB) 2e-5 s
-1
 20 
dm4 IkBb mRNA degradation 0.0004 s
-1
 43 
dm3 NFX mRNA degradation  s
-1
 * 
t4 IkBb translation rate 0.5 s
-1
 13 
t3 NFX translation rate  s
-1
 * 
i3 NFX nuclear import rate 0.09 s
-1
 * 















Supplement 1: Description of biochemical reactions and converting them to ordinary 
differential equations 
 
IKKn:  IKK in neutral state  
The first term describes IKKn synthesis; the second one describes the depletion of IKKn 
due to the TLR4 signal-induced transformation into active form IKKa, while the last one 
describes the spontaneous degradation. 
dIKKn / dt      =     kprod  -  k1 *  R0 *  IKKn * TLR4  -  kdeg * IKKn              (1) 
IKKa: IKK in active state 
The first line represents the activation of IKK by TLR4 signal, the deactivation of IKK 
induced by A20 and spontaneous deactivation of active IKK; The second line and the 
third line reprensent spontaneous degradation  of IKKa, depletion of free IKKa due to 
formation of complexes of IKKaIkBa and IKKaIkBaNFkB, and concentration change of 
IKKa due to dissociation of IKKaIkBa and IKKaIkBaNFkB complexes . The presence of 
NFkB enhances the effecient of IKKa and IkBa interaction by a factor f1[9]. The final 
line represents the concentration change due to catalysis. IKKa is still active after 
catalystic phosphralation. 
dIKKa/dt    =      k1 *  IKKn * TLR4  -  k2 * R0* A20* IKKa  -  k3 *  IKKa                  
                        -  kdeg * IKKa  -  a2 * IKKa * IkBa  -  a2 * f1 * IKKa * IkBaNFkB     (2) 
                        + d2 * IKKaIkBa  +  d2 * f1 * IKKaIkBaNFkB  
                        +  kcat * IKKaIkBa  + kcat * f2 * IKKaIkBaNFkB 
 
IKKi: inactive state of IKK 
First term describes inactive IKK forming due to A20, the second describes the 
concentration increase of IKKi due to IKKa spontaneous deactivation, while the third one 
represents the degradation of IKKi. IKKi is assued has the same spontaneous degradation 
rate as IKKn and IKKa. 
 
dIKKi/dt                         =  k2 * A20* IKKa + k3 *  IKKa - kdeg * IKKi                    (3) 





The first line describes the concentration change of IKKaIkBa due to IkBa 
associates ,dissociates with  IKKa and catalytic by IKKa; The second line represents 
association and dissociation between IKKaIkBa and NFkB. 
dIKKaIkBa/dt                =  a2 * IKKa * IkBa - d2 * IKKaIkBa - kcat * IKKaIkBa  
                                           –  a1 * NFkB * IKKaIkBa + d1 * IKKaIkBaNFkB         (4) 
IKKaIkBaNFkB: complex of IKKa, IkBa and NFkB 
The first line represents the association and dissociation between IKKaIkBa and NFkB; 
the second line represents the association and dissociation between IKKa and IkBaNFkB; 
The final line describel the depletion of IKKaIkBaNFkB due to the catalysis process. 
dIKKaIkBaNFkB/dt      =  a1 * NFkB * IKKaIkBa   - d1 * IKKaIkBaNFkB  
                                          + a2 * f1 * IKKa * IkBaNFkB - d2 * f1 * IKKaIkBaNFkB  (5) 
                                          - kcat * f2 * IKKaIkBaNFkB 
NFkB: Free cytoplasmic NFkB 
The first line describes free NFkB concentration increase due to dissociation of 
IkBaNFkB  and  IKKaIkBaNFkB; the second line describes the decrease of free NFkB 
due to association with IkBa, IKKaIkBa and shuttling into the nucleus. The final line 
represents the concentration increase due to IKKa catalytic degrading IkBa and 
spontonous degradation of bound IkBa. The factor f2 represents the effect of the presence 
of NFkB on IKKa phosphralating IkBa[9]. 
 
dNFkB/dt                       =  d1 * IkBaNFkB + d1 * IKKaIkBaNFkB  
                                        - a1 * NFkB * IkBa - a1 * NFkB * IKKaIkBa - i1 * NFkB   (6) 
                                        + kcat * f2 * IKKaIkBaNFkB + de3 * IkBaNFkB  
NFkBn: Free NFkB in the nucleus 
First term  and second represent free NFkBn changes due to dissociation and association 
between IkBa and NFkB in the nucleus; and the last term reprensents that NFkB imports 
to the nucleus from the cytoplasm. Because of the volume of cytoplasm is larger than the 
nucleus, kv = the volume of the cytoplasm / the volume of the nucleus, the concentration 
change due to importion is kv times of that in the cytoplasm. 
dNFkBn/dt                     =  d1 * IkBanNFkBn - a1 * NFkBn * IkBan + kv * i1 * NFkB  (7) 





First term discripes A20 protein production rate due to the translation from A20 mRNA; 
the second term represent degradation of A20 protein; and the final term represents that 
free A20 decreases because of inhibiting IKK activity. We assume that TLR4 
consductive signaling is required to activate A20. 
dA20/dt                          =  t2 * A20m - de2 * A20 - k2 * TLR4* A20* IKKa                 (8) 
A20m: A20 messenger RNA 
We seperate the synthesis of A20 mRNA to two parts. One is constuctive and the other is 
first-order dependent on free NFkB concentration in the nucleus. The last term represents 
first order degradation of A20 mRNA.  
dA20m/dt                       =  cs2 + s2 *  NFkBn - dm2* A20m                                          (9) 
IkBa: Free IkBa in the cytoplasm 
The first and second lines represent the concentration change of free IkBa due to the 
dissociation and association obetween IkBa and NFkB, and between IKKa and IkBa; the 
last line represents free IkBa protein importing to, exporting from the neucleus, 
translation form IkBa mRNA and spontanous degradation. 
dIkBa/dt                         =  d1 * IkBaNFkB - a1 * NFkB * IkBa  
                                           + d2 * IKKaIkBa - a2 * IKKa * IkBa                                  (10) 
                                           - i1a * IkBa + e1a * IkBan /kv + t1 * IkBam - de1 * IkBa 
 
 
IkBan: Free IkBa in the nucleus 
First line represents IkBa concentration change due to the dissociation and association 
between IkBa and NFkB; the sencond line represents IkBa concentration change caused 
by free IkBa shuttling between the cytoplasm and the nucleus. 
dIkBan/dt                       =  d1 * IkBanNFkBn - a1 * NFkBn * IkBan                        (11) 
                                            +  kv * i1a * IkBa - e1a * IkBan 
IkBam: IkBa messenger RNA 
We seperate the synthesis of IkBa mRNA to two parts. One is constuctive and the other is 
first-order dependent on free NFkB concentration in the nucleus. The last term represents 
first order degradation of IkBa mRNA.  





IkBaNFkB: cytoplasmic IkBaNFkB complex 
First line represents the concentration change of IkBaNFkB due to the association and 
dissociation between IkBa and NFkB; second line describes the the concentration change 
of IkBaNFkB due to the association and dissociation between IKKa and IkBa NFkB. 
NFkB increases the association rate of IKKa and IkBa according experimental data[9]. 
Based on the motif-motif  interaction principle, the affinity of IKKa and IkBa doesn’t 
change, so the dissociation between them also is increased by f1 times. The final line 
represents the exporting of IkBaNFkB from the nucleus and the degradation of 
IkBaNFkB. 
dIkBaNFkB/dt               =  a1 * NFkB * IkBa - d1 * IkBaNFkB  
                                           - a2 * f1 * IKKa * IkBaNFkB + d2 * f1 * IKKaIkBaNFkB (13) 
                                           + e2a * IkBanNFkBn / kv - de3 * IkBaNFkB  
IkBanNFkBn: IkBaNFkB complex in the nucleus 
First line represents the concentration change due to the association and dissociation 
between NFkBn and IkBan; the second line represents the exporting of  IkBan NFkBn  
from the nucleus. 
dIkBanNFkBn/dt           =  a1 * NFkBn * IkBan - d1 * IkBanNFkBn  
                                            - e2a * IkBanNFkBn                                                             (14) 
The second model will add IkBb into the signaling network. IkBb can reacte with IKKa 
and NFkB in the cytoplasm and can also bind with NFkB in the nucleus. The different of 
IkBb and IkBa is that IkBb is induced by an unknow nuclear factor X which is induced 
by NFkB. 10 more equations are added, described as below. However, the differential 
equations of IKK, NFkB and NFkBn will be changed due to their interaction with IkBb. 
IKKa: IKK in active state 
The first line represents the activation of IKK by TLR4 signal, the deactivation of IKK 
induced by A20 and spontaneous deactivation of active IKK; The second line and the 
third line reprensent spontaneous degradation  of IKKa, depletion of free IKKa due to 
formation of complexes of IKKaIkBa and IKKaIkBaNFkB, and concentration change of 
IKKa due to dissociation of IKKaIkBa and IKKaIkBaNFkB complexes . The presence of 
NFkB enhances the effecient of IKKa and IkBa interaction by a factor f1[9]. The fourth 





catalystic phosphralation. IKKa can also phosprolate IkBb. The last three lines represents 
the association between IKKa and IkBb, IKKa and IkBbNFkB, and catalysis of 
IKKaIkBb and IKKaIkBbNFkB. Factors f3 and f4 represent the effects of NFkB on IKKa 
associating and catalysizing IkBb. 
 
dIKKa/dt    =      k1 *  IKKn * TLR4  -  k2 * R0* A20* IKKa  -  k3 *  IKKa                  
                        -  kdeg * IKKa  -  a2 * IKKa * IkBa  -  a2 * f1 * IKKa * IkBaNFkB     (2*) 
                        + d2 * IKKaIkBa  +  d2 * f1 * IKKaIkBaNFkB  
                        +  kcat * IKKaIkBa  + kcat * f2 * IKKaIkBaNFkB 
                        -  a4 * IKKa * IkBb  -  a4 * f3 * IKKa * IkBbNFkB         
                        + d4 * IKKaIkBb  +  d4 * f3* IKKaIkBbNFkB  
                        +  kcat * IKKaIkBb  + kcatb * f4 * IKKaIkBbNFkB 
 
 
NFkB: Free cytoplasmic NFkB 
The first line describes free NFkB concentration increase due to dissociation of 
IkBaNFkB  and  IKKaIkBaNFkB; the second line describes the decrease of free NFkB 
due to association with IkBa, IKKaIkBa and shuttling into the nucleus. The Third line 
represents the concentration increase due to IKKa catalytic degrading IkBa and 
spontonous degradation of bound IkBa. The factor f2 represents the effect of the presence 
of NFkB on IKKa phosphralating IkBa[9]. The last three lines represent the concentration 
of NFkB due to its dissociation and association with IkBb, IKKaIkBb, and degradation of 
IkBb due to IKKa phospralation and spontanous degradation. 
 
dNFkB/dt                       =  d1 * IkBaNFkB + d1 * IKKaIkBaNFkB  
                                        - a1 * NFkB * IkBa - a1 * NFkB * IKKaIkBa - i1 * NFkB   (6*) 
                                        + kcat * f2 * IKKaIkBaNFkB + de3 * IkBaNFkB  
                                        + d3 * IkBbNFkB + d3 * IKKaIkBbNFkB  
                                        - a3 * NFkB * IkBb – a3 * NFkB * IKKaIkBb 







NFkBn: Free NFkB in the nucleus 
First term  and second represent free NFkBn changes due to dissociation and association 
between IkBa and NFkB in the nucleus; and the third term reprensents that NFkB imports 
to the nucleus from the cytoplasm. Because of the volume of cytoplasm is larger than the 
nucleus, kv = the volume of the cytoplasm / the volume of the nucleus, the concentration 
change due to importion is kv times of that in the cytoplasm. The last line represents the 
dissociation and association between NFkB and IkBb in the nucleus. 
dNFkBn/dt                   =    d1 * IkBanNFkBn - a1 * NFkBn * IkBan + kv * i1 * NFkB  
                                           + d3 * IkBbnNFkBn – a3 * NFkBn * IkBbn                         (7*) 
IkBb: Free IkBb in the cytoplasm 
The first and second lines represent the concentration change of free IkBb due to the 
dissociation and association obetween IkBb and NFkB, and between IKKa and IkBb; the 
last line represents free IkBb protein importing to, exporting from the neucleus, 
translation form IkBb mRNA and spontanous degradation. 
dIkBb/dt                         =  d3 * IkBbNFkB – a3 * NFkB * IkBb  
                                           + d4 * IKKaIkBb – a4 * IKKa * IkBb                                 (15) 
                                           - i1b * IkBb + e1b * IkBbn /kv + t4 * IkBbm – de4 * IkBb 
 
IkBbNFkB: cytoplasmic IkBbNFkB complex 
First line represents the concentration change of IkBbNFkB due to the association and 
dissociation between IkBb and NFkB; second line describes the the concentration change 
of IkBbNFkB due to the association and dissociation between IKKa and IkBb NFkB. 
NFkB increases the association rate of IKKa and IkBb according experimental data[9]. 
Based on the motif-motif  interaction principle, the affinity of IKKa and IkBb doesn’t 
change, so the dissociation between them also is increased by f3 times. The final line 
represents the exporting of IkBbNFkB from the nucleus and the degradation of 
IkBbNFkB. 
 
dIkBaNFkB/dt               =  a3 * NFkB * IkBa – d3 * IkBbNFkB  





                                          + e2b * IkBbnNFkBn / kv – de5 * IkBbNFkB                      (16) 
 
IKKaIkBb: complex of IKKa and IkBb 
The first line describes the concentration change of IKKaIkBb due to IkBb 
associates ,dissociates with  IKKa and catalytic by IKKa; The second line represents 
association and dissociation between IKKaIkBb and NFkB. 
dIKKaIkBa/dt                =  a4 * IKKa * IkBb – d4 * IKKaIkBb - kcatb * IKKaIkBb  
                                           –  a3 * NFkB * IKKaIkBb + d3 * IKKaIkBbNFkB           (17) 
IKKaIkBbNFkB: complex of IKKa, IkBb and NFkB 
The first line represents the association and dissociation between IKKaIkBb and NFkB; 
the second line represents the association and dissociation between IKKa and IkBbNFkB; 
The final line describel the depletion of IKKaIkBbNFkB due to the catalysis process. 
dIKKaIkBbNFkB/dt      =  a3 * NFkB * IKKaIkBb   - d3 * IKKaIkBbNFkB  
                                         + a4 * f3 * IKKa * IkBbNFkB – d4 * f3 * IKKaIkBbNFkB  (18) 
                                          - kcatb * f4 * IKKaIkBbNFkB 
IkBbm: IkBb messenger RNA 
We seperate the synthesis of IkBb mRNA to two parts. One is constuctive and the other 
is first-order dependent on free NFkB concentration in the nucleus. The last term 
represents first order degradation of IkBb mRNA.  
dIkBbm/dt                      =    cs4 + s4 *  NFkBn – dm4 * IkBbm                                    (19) 
NFX: unknown transcription factor 
There is a time delay for IkBb transcription  following NFkB activity.[23] This time 
delay may be caused by an intermidate transcription factor, like foxj1[24] . But we don’t 
know much about this intermidate transcription factor. In the following equation, the first 
term represents the production of NFX translation from RNA, and the second  and the 
third terms describe the concentration change of NFX due to shuttling between the 
cytoplasm and the nucleus; the final term represents the degradation of NFX. 
dNFX/dt                        =  t3 * NFXm - i3 * NFX + e3 * NFXn /kv - de6 * NFX        (20)  
NFXn: NFX in the nucleus 
First term represents NFX imports to the nucleus while the second term represents its 





dNFXn/dt                      =  kv * i3 * NFX - e3 * NFXn                                                  (21)    
NFXm: NFX messenger RNA     
We assumethat NFX is produced by two parts, one is constudctive synthesis rate cs3, and 
another part is induced by NFkB.  The first term represents the constudctive synthesis of 
NFX mRNA and the second represents the inducible synthesis, while the final one 
represnts the degradation of NFX mRNA.                                              
dNFXm/dt                     = cs3 + s3 *  NFkBn - dm3 * NFXm                                       (22)                                          
IkBbn: Free IkBb in the nucleus 
First line represents IkBb concentration change due to the dissociation and association 
between IkBb and NFkB; the sencond line represents IkBb concentration change caused 
by free IkBb shuttling between the cytoplasm and the nucleus. 
dIkBbn/dt                       =  d3 * IkBbnNFkBn – a3 * NFkBn * IkBban                        (23) 
                                            +  kv * i1b * IkBb - e1b * IkBbn 
IkBbnNFkBn: IkBbNFkB complex in the nucleus 
First line represents the concentration change due to the association and dissociation 
between NFkBn and IkBan; the second line represents the exporting of  IkBbnNFkBn  
from the nucleus. 
dIkBbnNFkBn/dt           =  a3 * NFkBn * IkBbn – d3 * IkBbnNFkBn  

















Supplement 2: Mathatical models coded in Matlab 
% calc_Yhat_nfkb_01.m 
 
function Y_hat = calc_Yhat_nfkb_01(k, X_pred); 
 
%Dimension declarations: 
n_diffeqn = 14; 
n_algeb   =0; 
n_tot     = n_diffeqn + n_algeb; 
id        = ones(n_diffeqn,1); 
id(n_diffeqn+1:n_tot) = zeros(n_algeb,1); 
 
%Initial conditions: 
[y0, data] = loadParams01(k, n_tot); 
t0         = 0; 
% set up options 
% 
options = CVodeSetOptions('RelTol',1.e-6,'AbsTol',1.e-6,... 
                          'NonlinearSolver','Newton','MaxNumSteps',6000); 
CVodeMalloc(@nfkb_core01,t0,y0,options,data); 
tp0 = X_pred(1,1)-60*10; 
[status,t,y] = CVode(tp0,'Normal'); 
if (status == 0) 
        yp0 = y; 
    else  
        yp0 = eps.*ones(n_tot,1); 
    end; 
   iout = 1; 
   Y    = zeros(1,n_tot); 
Y(1,:)  = yp0'; 





while iout < nout 
    % update output time 
    tout = X_pred(iout+1); 
    [status,t,y] = CVode(tout,'Normal'); 
    if (status == 0) 
        yout = y; 
    else  
        yout = eps.*ones(n_tot,1); 
    end; 
    Y = [Y; yout']; 




% post-processing to compare to experimental data- free nuclear NFkB 
%-------------------------------------------------------------------- 
 
%free nuclear NFkB 
Free_NFkBn = zeros(size(Y,1),1); 
Free_NFkBn = Y(:,7); 
detect = yp0(7); 
detect2= yp0(4)+yp0(5)+yp0(10)+yp0(13); 
Yhat1 = Free_NFkBn ./ detect; 
% total cytoplasmic IkB protein and complex 
TotalIkB = zeros(size(Y,1),1); 
TotalIkB = Y(:,4)+ Y(:,5)+ Y(:,10) + Y(:,13); 
Yhat2 = TotalIkB./ detect2; 
%extract response predictions 








function[dydt, FLAG, NEW_DATA]=nfkb_core01(t,y_nfkb,data) 
%dydt=zeros(size(y_nfkb)); 
% 
%unpack initial concentrations 
% 
params        = data.params; 
tstart        = data.tstart; 
IKKn         = y_nfkb(1); % Free unactivated cytoplasmic IKK protein 
IKKa         = y_nfkb(2); % Free activated cytoplasmic IKK protein 
IKKi         = y_nfkb(3); % Free deactivated cytoplasmic IKK protein 
IKKaIkBa     = y_nfkb(4); % Cytoplasmic IKKa-IkBa complexes 
IKKaIkBaNFkB = y_nfkb(5); % Cytoplasmic IKKa-IkBa-NFkB protein 
NFkB         = y_nfkb(6); % Free  cytoplasmic NF-kB protein 
NFkBn        = y_nfkb(7); % Free  nuclear NF-kB protein 
A20          = y_nfkb(8); % Cytoplasmic A20 protein 
A20m         = y_nfkb(9); % A20 mRNA 
IkBa         = y_nfkb(10); % Free  cytoplasmic IkBa protein 
IkBan        = y_nfkb(11); % Free  nuclear IkBa protein 
IkBam        = y_nfkb(12); % IkBa m RNA 
IkBaNFkB     = y_nfkb(13); % Cytoplasmic IkBa-NFkB complexes 




start1 = tstart(1,1); 
start2 = tstart(1,2); 
start3 = tstart(1,3); 
% 
%==============================================================








a1  = 10^params(1,1); %0.5 % microM-1 sec- IKBa2NFkB association Hoffmann et al. 
a2  = 10^params(2,1); % mM-1 sec-1 IKKa IkBa association fitting 
f1  = 10^params(3,1); %0.2 the factor of NFkB on IKKa-IkBa association Hoffmann et al. 
kcat= 10^params(4,1); % sec-1 IKKajIkBa catalysis fitting 
f2  = 10^params(5,1); %5% the factor of NFkB on IKKa-IkBa catalysis Hoffmann et al 
d1  = 10^params(6,1); %IkBa-NFkB reversible dissociation rate 1.25e-3 s-1
 (2) 
d2  = 10^params(7,1); %IKK-IkBa reversible dissociation rate 0.5e-3 s-1 (2) 
s1  = 10^params(8,1); % 5.0e7 % sec-1 IkBa-inducible mRNA synthesis fitting 
cs1 = 10^params(9,1); % 0.0 % mM sec-1 IkBa-constitutive mRNA synthesis 
Assumption 
dm1 = 10^params(10,1); % 0.0004 % sec-1 IkBa mRNA degradation Fitted, Blattner et al. 
t1  = 10^params(11,1); % 0.5 % sec-1 IkBa translation rate Fitted lipniak 2004 
de1 = 10^params(12,1); % 0.0001 % sec-1 Spontaneous, free IkBa protein degradation 
Pando and Verma (2000) 
de3 = 10^params(13,1); % 0.00002 % sec-1 IkBa degradation (complexed to NF-kB) 
Pando and Verma (2000) 
s2  = 10^params(14,1); % sec-1 A20-inducible mRNA synthesis fitting 
cs2 = 10^params(15,1); % 0.0 % mM sec-1 A20-constitutive mRNA synthesis 
Assumption 
dm2  = 10^params(16,1); %  sec-1 A20 mRNA degradation fitting 
t2  = 10^params(17,1); % 0.5 % sec-1 A20 translation rate fitting 
de2  = 10^params(18,1); % 0.0003 % sec-1 A20 protein degradation Fitted 
k1  = 10^params(19,1); % 0.0025 % sec-1 IKK activation rate caused by TNF Fitted 
k2  = 10^params(20,1); % 0.1 % sec-1 IKK inactivation rate caused by A20 Fitted 
k3  = 10^params(21,1); % 0.0015 % sec-1 IKK spontaneous inactivation rate Fitted 
kprod = 10^params(22,1); % 0.000025 % mM sec-1 IKKn production rate Fitted 





                      %NF 0:06 V mM V Total amount of free and complexed NF-kB 
Assumption, Carlotti 
kv  = 10^params(24,1); % 5 % Cytoplasmic to nuclear volume Assumption 
i1  = 10^params(25,1); % 0.0025 % sec-1 NF-kB nuclear import Fitted 
i1a = 10^params(26,1); % 0.001 % sec-1 IkBa nuclear import Fitted 
e1a = 10^params(27,1); % 0.0005 % sec-1 IkBa nuclear export Assumption 
e2a = 10^params(28,1); % 0.01 % sec-1 (IkBajNF-kBÞ nuclear export Fitted 
kd1 = 10^params(29,1); % 0.1 % mM Dissociation constant for NF-kB to kB1 sites 
kd2 = 10^params(30,1); % 0.1 % mM Dissociation constant for NF-kB to kB2 sites 
inhibited by DCPA 
alpha1 = 10^params(31,1);% effect of DCPA on activation of IKK 
alpha2 = 10^params(32,1);% effect of DCPA on inducible production of IkBat 
dcpa   = 10^params(33,1); %DCPA concentration 
% 
% Rate equations 
% 
R0 =1.0 * (erf(2*(t-start2))-erf(2*(t-start3))); 
R0a=dcpa * (erf(2*(t-start2))-erf(2*(t-start3))); 
DCPA = R0a; 
TLR4 = 1; 
%Reaction class 1: IkBa-NFkB Association 
R1a = a1 * NFkB * IkBa; 
R1b = a1 * NFkBn * IkBan; 
R1c = a1 * NFkB * IKKaIkBa; 
 
%Reaction class 2: IKKa-IkBa Association 
R2a  = a2 * IKKa * IkBa; 
R2b = a2 * f1 * IKKa * IkBaNFkB; 
 
%Reaction class 3: IkBa-NFkB  dissociation  





R3b = d1 * IkBanNFkBn; 
R3c = d1 * IKKaIkBaNFkB; 
 
%Reaction class 4: IKKa-IkBa  dissociation  
R4a = d2 * IKKaIkBa; 
R4b = d2 * f1 * IKKaIkBaNFkB; 
 
%Reaction class 5: IKKa-IkBa Catalytic dissociation 
R5a  = kcat * IKKaIkBa;%* (1 + alpha1*DCPA/(DCPA+kd1)); 
R5b  = kcat * f2 * IKKaIkBaNFkB;%* (1 + alpha1*DCPA/(DCPA+kd1)); 
 
%Reaction class 6:  Degradation of  IKK 
R6a = kdeg * IKKn; 
R6b = kdeg * IKKa; 
R6c = kdeg * IKKi; 
 
%Reaction class 7: Degradation of   free IkBa proteins 
R7  = de1 * IkBa; 
 
%Reaction class 8: Degradation of  IkBa complex to NFkB 
R8  = de3 * IkBaNFkB; 
 
%Reaction class 9: Degradation of  A20 proteins 
R9  = de2 * A20; 
 
%Reaction class 10: Degradation of  IkBa mRNA 
R10  = dm1 * IkBam; 
 
%Reaction class 11: Degradation of  A20 mRNA 






%Reaction class 12: Synthesis of IKKn 
R12  = kprod; 
 
%Reaction class 13: Inducible synthesis of IkBa mRNA 
R13  = s1 *  NFkBn * (1 - alpha2  *  DCPA / ( DCPA+kd2 )); 
 
%Reaction class 14: Inducible synthesis of A20 mRNA 
R14  = s2 *  NFkBn * (1 - alpha2  *  DCPA / ( DCPA+kd2 )); 
 
%Reaction class 15: Constitutive synthesis of IkBa mRNA 
R15  =  cs1; 
 
%Reaction class 16: Constitutive synthesis of A20 mRNA 
R16  = cs2; 
 
%Reaction class 17: Translation from IkBa mRNA to IkBa proteins 
R17 = t1 * IkBam; 
 
%Reaction class 18: Translation from A20 mRNA to A20 proteins 
R18= t2 * A20m; 
 
%Reaction class 19: Activation of IKKn to IKKa 
R19= k1 *  R0 *  IKKn * TLR4 *  (1 + alpha1*DCPA/(DCPA+kd1)); 
 
%Reaction class 20: Inactivation of IKKa because of A20 
R20 = k2 * R0* A20* IKKa; 
 
%Reaction class 21: Spontaneous Inactivation of IKKa to IKKi 
R21= k3 *  IKKa; 
 





R22= i1a * IkBa; 
 
%Reaction class 23: IkBa export from the nucleus to cytoplasm 
R23 = e1a * IkBan; 
 
%Reaction class 24: IkBanNFkBn export from the nucleus to cytoplasm 
R24 = e2a * IkBanNFkBn; 
 
%Reaction class 25: NFkB import to the nucleus from cytoplasm 
R25 = i1 * NFkB *  (1 + alpha2*DCPA/(DCPA+kd1)); 
 
%Differential equations that define the mathematical model for NFkB signaling pathway. 
 
dydt(1)  =  R12 - R19 - R6a;                                         % IKKn 
dydt(2)  =  R19 - R20 - R21- R6b - R2a - R2b + R4a + R4b + R5a + R5b; %IKKa 
dydt(3)  =  R20 + R21 - R6c;                                         %IKKi 
dydt(4)  =  R2a - R4a - R5a - R1c + R3c;                   %IKKaIkBa/dt  
dydt(5)  =  R1c + R2b- R3c - R4b - R5b;                   %IKKaIkBaNFkB/dt 
dydt(6)  =  R3a + R3c - R1a- R1c + R5b + R8 - R25;        %NFkB/dt    
dydt(7)  =  R3b + kv * R25 - R1b;                         %NFkBn/dt  
dydt(8)  =  R18 - R9 - R20;                               %dA20/dt   
dydt(9)  =  R16 + R14 -R11;                               %dA20m/dt     
dydt(10) =  R3a -R1a + R4a -R2a -R22+R23/kv +R17-R7;      %dIkBa/dt  
dydt(11) =  R3b - R1b +  kv * R22 - R23;                  %dIkBan/dt   
dydt(12) =  R13+ R15 - R10;                               %dIkBam/dt  
dydt(13) =  R1a - R3a - R2b +R4b + R24 / kv - R8;         %dIkBaNFkB/dt  
dydt(14) =  R1b - R3b - R24;                              %dIkBanNFkBn/dt    
 
 
FLAG = 0; 






function [y0, data] = loadParams01(k, n_tot) 
 
% Initial conditions: 
y0       = zeros(n_tot,1); 
y0(1,1)  = 0.02;             % mico M IKKn 
%y0(10,1) = 0.06;          % Rice and Ernst(1993) 






params       = zeros(33,1);  
params(1,1)  = log10(0.5 );    % 0.5 a1  microM-1 sec-1 IkBa-NFkB association 
Hoffmann et al. (2002) 
params(2,1)  = log10(0.0225);         % a2  microM-1 sec-1 IKKa-IkBa association 
Assumption 
params(3,1)  = log10(7);               %5 f1 the factor of NFkB on IKKa-IkBa association 
Hoffmann et al. 
params(4,1)  = log10(0.00407);          % kcat  % sec-1 IKKajIkBa catalysis fitting 
params(5,1)  = log10(5) ;               %f2% the factor of NFkB on IKKa-IkBa catalysis 
Hoffmann et al 
params(6,1)  = log10(0.0005);          %d1 %IkBa-NFkB reversible dissociation rate
 1.25e-3 s-1 (2) 
params(7,1)  = log10(1.25e-3);         % d2  = 10^params(7,1); %IKK-IkBa reversible 
dissociation rate 0.5e-3 s-1 (2) 
params(8,1)  = k(1,1) ;         % s1  = 10^params(8,1); % 5.0e7 % sec-1 IkBa-inducible 
mRNA synthesis fitting 
params(9,1)  = log10(1.0256e-11); % cs1 = 10^params(9,1); % 0.0 % mM sec-1 IkBa-





params(10,1) = log10(0.0004);   % dm1 = 10^params(10,1); % 0.0004 % sec-1 IkBa 
mRNA degradation Fitted, Blattner et al. 
params(11,1) = k(2,1);       % t1  = 10^params(11,1); % 0.5 % sec-1 IkBa translation rate 
Fitted lipniak 2004 
params(12,1) = log10(0.000113);   % de1 = 10^params(12,1); % 0.0001 % sec-1 
Spontaneous, free IkBa protein degradation Pando and Verma (2000) 
params(13,1) = log10(0.0000225);  % de3 = 10^params(13,1); % 0.00002 % sec-1 IkBa 
degradation (complexed to NF-kB) Pando and Verma (2000) 
params(14,1) = k(3,1);          % s2  = 10^params(14,1); % sec-1 A20-inducible mRNA 
synthesis fitting 
params(15,1) = k(4,1);   % cs2 = 10^params(15,1); % 0.0 % mM sec-1 A20-constitutive 
mRNA synthesis Assumption 
params(16,1) = k(5,1);          %dm2  = 10^params(16,1); %  sec-1 A20 mRNA 
degradation fitting 
params(17,1) = k(6,1);          %t2  = 10^params(17,1); % 0.5 % sec-1 A20 translation rate 
fitting 
params(18,1) = log10(0.0003);   % de2  = 10^params(18,1); % 0.0003 % sec-1 A20 
protein degradation Fitted 
params(19,1) = k(7,1);         % k1 sec-1     0.0025 IKK activation rate caused by TNF 
Fitted 
params(20,1) = k(8,1);      % k2 sec-1     IKK inactivation rate caused by A20 Fitted 
params(21,1) = log10(3.2374e-10);       % k3 sec-1     IKK spontaneous inactivation rate 
Fitted 
params(22,1) = k(9,1) ;      %kprod IKKn synthesis rate 
params(23,1) = k(10,1);     % kdeg sec-1   IKKa, IKKn and IKKi degradation Fitted 
params(24,1) = log10(7);         % kv  7         Cytoplasmic to nuclear volume Assumption 
7 Cheong 2006, 5 Lipniacki 2004, 2006 
params(25,1) = k(12,1);%log10(0.0013);  % i1  sec-1    NF-kB nuclear import Fitted  
                                %0.0025 Lipniacki 2004, 2006; 0.09 Werner 2005  
params(26,1) = k(11,1)+log10(2);   % i1a sec-1    IkBa nuclear import Fitted  





params(27,1) = k(11,1);   % e1a sec-1    IkBa nuclear export Assumption  
                                %0.0005 Lipniacki 2004, 0.005 Lipniacki 2006, 0.0002 Werner 2005  
params(28,1) = k(13,1);  % e2a sec-1    IkBa-NF-kB nuclear export Fitted  
 %0.01 Lipniacki 2004, 0.05 Lipniacki 2006, 0.014 Werner 2005 
 
params(29,1) = log10(5);         % kd1 mM       Half-maximum DCPA concentration 
params(30,1) = log10(5);         % kd2 mM       Half-maximum DCPA concentration 
params(31,1) = log10(0.48);         % alpha1         Effect of DCPA on activating IKK 
params(32,1) = log10(0.013);       % alpha2  effect of DCPA on NFkB inducible 
producing IkBa mRNA  
params(33,1) = log10(1.0e-20 );   %DCPA  concentration  is 100 uM     
                            
if size(params,1) == 1  
    params = params';            % convert K to a column vector instead of a row vector 
end; 
 
% start and stop times of LPS bolus in nfkb_core01 file 
tstart = [0 2000*60 6*60*60+2000*60]; 
%pack parameters into data struct 
data.params = params; 
data.tstart  = tstart; 
 
return; 
function [kin] = InitParams01() 
% Load paramaters - mean values from MCMC run 
kin = zeros(13,1); 
 
kin(1,1)  = log10(4.2615e-5);   % s1  = 10^params(8,1); % 5.0e7 % sec-1 IkBa-inducible 
mRNA synthesis fitting 
%kin(2,1)  = log10(1.0256e-11) ; % cs1 = 10^params(9,1); % 0.0 % mM sec-1 IkBa-





kin(2,1)  = log10(0.6592); % t1 IkBa translation rate 
kin(3,1)  = log10(0.0967 );    % s2  = 10^params(14,1); % sec-1 A20-inducible mRNA 
synthesis fitting 
kin(4,1)  = log10(8.634e-7);   % cs2 = 10^params(15,1); % 0.0 % mM sec-1 A20-
constitutive mRNA synthesis Assumption 
kin(5,1)  = log10(0.0716);   % dm2  = 10^params(16,1); %  sec-1 A20 mRNA 
degradation fitting 
kin(6,1)  = log10(0.4138);  %t2  = 10^params(17,1); % 0.5 % sec-1 A20 translation rate 
fitting 
kin(7,1)  = log10(0.0016);   % k1 sec-1     0.0025 IKK activation rate caused by TNF 
Fitted 
kin(8,1)  = log10(0.2462);     % k2 sec-1     IKK inactivation rate caused by A20 Fitted 
%kin(10,1) = log10(3.2374e-10);   % k3 sec-1     IKK spontaneous inactivation rate 
Fitted 
kin(9,1) = log10(4.707e-4); % kprod microM sec-1 IKKn production rate Fitted 
kin(10,1) = log10(0.0031); % kdeg sec-1   IKKa, IKKn and IKKi degradation Fitted 
kin(11,1) = log10(1.3858e-4);   % e1a sec-1    IkBa nuclear export Assumption  
                                %0.0005 Lipniacki 2004, 0.005 Lipniacki 2006, 0.0002 Werner 2005  
kin(12,1) = log10(4.3958e-4);  % i1  sec-1    NF-kB nuclear import Fitted  
                                %0.0025 Lipniacki 2004, 2006; 0.09 Werner 2005  
kin(13,1) = log10(0.002);  % e2a sec-1    IkBa-NF-kB nuclear export Fitted                                 
if size(kin,1) == 1 




function [data] = data_nfkb01 

























%data(1).ppn = 0; 
%data(1).tdata = tdata .*60+ 2000*60; 
%data(1).values = [[1 1];[1.47 1];[3 0];[6.51 1];[7.5 0];[10 0];[9.71 1];[13 0];[19 0];[22 
0];[16 0];[13.22 1];[28 0];[31 0];[33 0];[34.5 0];[39 0];[6.43 1];[42 0];[43 0];[45 0];[47 
0];[49 0];[51 0];[53 0];[5.64 1];[57 0];[59 0];[61 0];[63 0];[65 0];[67 0];[69 0];[5.27 
1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[10.08 1];[73 0];[75 0];[77 0];[79 
0];[81 0];[83 0];[85 0];[9.28 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[6.95 
1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 
0];[85 0];[5.67 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 
0];[81 0];[83 0];[85 0];[7.31 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 
0];[77 0];[79 0];[81 0];[83 0];[85 0];[7.51 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[6.88 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[6.77 0];[73 0];[75 0];[77 
0];[79 0];[81 0];[83 0];[85 0];[7.84 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 





% total cytoplasmic IkB 
%data(1).values = [[1 1];[1.47 1];[3 0];[6.51 1];[7.5 0];[10 0];[9.71 1];[13 0];[19 0];[22 
0];[16 0];[13.22 1];[28 0];[31 0];[33 0];[34.5 0];[39 0];[6.43 1];[42 0];[43 0];[45 0];[47 
0];[49 0];[51 0];[53 0];[5.64 1];[57 0];[59 0];[61 0];[63 0];[65 0];[67 0];[69 0];[5.27 
1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[10.08 1];[73 0];[75 0];[77 0];[79 
0];[81 0];[83 0];[85 0];[9.28 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[6.95 
1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 
0];[85 0];[5.67 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 
0];[81 0];[83 0];[85 0];[7.31 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 
0];[77 0];[79 0];[81 0];[83 0];[85 0];[7.51 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[6.88 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[6.77 1];[73 0];[75 0];[77 
0];[79 0];[81 0];[83 0];[85 0];[7.84 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[7.47 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[8.23 1]]; 
% Cyto. IkBa 
%data(3).ppn = 0; 
%data(3).tdata = tdata .*60+ 2000*60; 
%data(3).values = [[1 1];[0.97 1];[3 0];[0.567 1];[7.5 0];[10 0];[0.255 1];[13 0];[19 0];[22 
0];[16 0];[0.482 1];[28 0];[31 0];[33 0];[34.5 0];[39 0];[0.950 1];[42 0];[43 0];[45 0];[47 
0];[49 0];[51 0];[53 0];[0.764 1];[57 0];[59 0];[61 0];[63 0];[65 0];[67 0];[69 0];[0.794 
1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.769 1];[73 0];[75 0];[77 0];[79 
0];[81 0];[83 0];[85 0];[0.592 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.587 
1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 
0];[85 0];[0.663 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 
0];[79 0];[81 0];[83 0];[85 0];[0.608 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.733 0];[73 0];[75 0];[77 0];[79 
0];[81 0];[83 0];[85 0];[0.688 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.849 
0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.693 0];[73 0];[75 0];[77 0];[79 
0];[81 0];[83 0];[85 0];[0.869 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.608 0]]; 
%data(3).values = [[1 1];[0.97 1];[3 0];[0.567 1];[7.5 0];[10 0];[0.255 1];[13 0];[19 0];[22 
0];[16 0];[0.482 1];[28 0];[31 0];[33 0];[34.5 0];[39 0];[0.950 1];[42 0];[43 0];[45 0];[47 





1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.769 1];[73 0];[75 0];[77 0];[79 
0];[81 0];[83 0];[85 0];[0.592 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.587 
1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 
0];[85 0];[0.663 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 
0];[79 0];[81 0];[83 0];[85 0];[0.608 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.733 1];[73 0];[75 0];[77 0];[79 
0];[81 0];[83 0];[85 0];[0.688 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.849 
1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.693 1];[73 0];[75 0];[77 0];[79 
0];[81 0];[83 0];[85 0];[0.869 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.608 1]]; 
 
%Experiment 2 
%data(2).ppn = 100; 
%data(2).tdata = tdata.*60+2000*60; 
%data(2).values = [[1 1];[1.41 1];[3 0];[5.60 1];[7.5 0];[10 0];[11.11 1];[13 0];[19 0];[22 
0];[16 0];[10.77 1];[28 0];[31 0];[33 0];[34.5 0];[39 0];[6.01 1];[42 0];[43 0];[45 0];[47 
0];[49 0];[51 0];[53 0];[6.21 1];[57 0];[59 0];[61 0];[63 0];[65 0];[67 0];[69 0];[7.93 
1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[9.29 1];[73 0];[75 0];[77 0];[79 0];[81 
0];[83 0];[85 0];[7.49 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[5.72 1];[73 
0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[5.75 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 0];[81 
0];[83 0];[85 0];[8.80 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 
0];[79 0];[81 0];[83 0];[85 0];[7.58 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[6.84 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[6.57 0];[73 0];[75 0];[77 
0];[79 0];[81 0];[83 0];[85 0];[8.18 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[7.78 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[9.20 0]]; 
%data(2).values = [[1 1];[1.41 1];[3 0];[5.60 1];[7.5 0];[10 0];[11.11 1];[13 0];[19 0];[22 
0];[16 0];[10.77 1];[28 0];[31 0];[33 0];[34.5 0];[39 0];[6.01 1];[42 0];[43 0];[45 0];[47 
0];[49 0];[51 0];[53 0];[6.21 1];[57 0];[59 0];[61 0];[63 0];[65 0];[67 0];[69 0];[7.93 
1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[9.29 1];[73 0];[75 0];[77 0];[79 0];[81 
0];[83 0];[85 0];[7.49 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[5.72 1];[73 





0];[5.75 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 0];[81 
0];[83 0];[85 0];[8.80 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 
0];[79 0];[81 0];[83 0];[85 0];[7.58 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[6.84 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[6.57 1];[73 0];[75 0];[77 
0];[79 0];[81 0];[83 0];[85 0];[8.18 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[7.78 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[9.20 1]]; 
%Cyto.IkBa 
 
% total cytoplasmic IkB 
%data(4).ppn = 100; 
%data(4).tdata = tdata .*60+ 2000*60; 
%data(4).values = [[0.949 1];[0.864 1];[3 0];[0.376 1];[7.5 0];[10 0];[0.235 1];[13 0];[19 
0];[22 0];[16 0];[0.430 1];[28 0];[31 0];[33 0];[34.5 0];[39 0];[0.928 1];[42 0];[43 0];[45 
0];[47 0];[49 0];[51 0];[53 0];[0.726 1];[57 0];[59 0];[61 0];[63 0];[65 0];[67 0];[69 
0];[0.897 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.630 1];[73 0];[75 0];[77 
0];[79 0];[81 0];[83 0];[85 0];[0.559 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[0.544 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 
0];[81 0];[83 0];[85 0];[0.623 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 
0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.552 1];[73 0];[75 0];[77 0];[79 0];[81 
0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.596 0];[73 0];[75 
0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.545 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 
0];[85 0];[0.771 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.589 0];[73 0];[75 
0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.558 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 
0];[85 0];[0.532 0]]; 
%data(4).values = [[0.949 1];[0.864 1];[3 0];[0.376 1];[7.5 0];[10 0];[0.235 1];[13 0];[19 
0];[22 0];[16 0];[0.430 1];[28 0];[31 0];[33 0];[34.5 0];[39 0];[0.928 1];[42 0];[43 0];[45 
0];[47 0];[49 0];[51 0];[53 0];[0.726 1];[57 0];[59 0];[61 0];[63 0];[65 0];[67 0];[69 
0];[0.897 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.630 1];[73 0];[75 0];[77 
0];[79 0];[81 0];[83 0];[85 0];[0.559 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 
0];[0.544 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 





0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.552 1];[73 0];[75 0];[77 0];[79 0];[81 
0];[83 0];[85 0];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.596 1];[73 0];[75 
0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.545 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 
0];[85 0];[0.771 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.589 1];[73 0];[75 
0];[77 0];[79 0];[81 0];[83 0];[85 0];[0.558 1];[73 0];[75 0];[77 0];[79 0];[81 0];[83 











data(1).ppn = 0; 
data(1).tdata = tdata .*60+ 2000*60; 
%NFkB in the nucleas 
data(1).values = [[1 1];[1 0];[1 0];[1 0];[1.47 1];[1 0];[1 0];[6.51 1];[1 0];[1 0];[9.71 1];[1 
0];[1 0];[1 0];[1 0];[13.22 1];[1 0];[1 0];[1 0];[1 0];[6.43 1];[1 0];[1 0];[1 0];[1 0];[5.64 
1];[1 0];[1 0];[1 0];[1 0];[5.27 1];[1 0];[1 0];[1 0];[1 0];[10.08 1];[1 0];[1 0];[1 0];[1 
0];[9.28 0];[1 0];[1 0];[1 0];[1 0];[1 0];[6.95 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[5.67 
0];[1 0];[1 0];[1 0];[1 0];[1 0];[7.31 0];[1 0];[1 0];[1 0];[1 0];[1 0];[7.51 0];[1 0];[1 0];[1 
0];[1 0];[1 0];[6.88 0];[1 0];[1 0];[1 0];[1 0];[1 0];[6.77 0];[1 0];[1 0];[1 0];[1 0];[1 
0];[7.84 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[7.47 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 
0];[8.23 0]]; 
% total IkBa in the cytoplasm 
data(3).ppn = 0; 





data(3).values = [[1.0 1];[1 0];[1 1];[1 0];[0.97 1];[1 0];[1 0];[0.57 1];[1 0];[1 0];[0.26 
1];[1 0];[1 0];[1 0];[1 0];[0.48 1];[1 0];[1 0];[1 0];[1 0];[0.95 1];[1 0];[1 0];[1 0];[1 
0];[0.76 1];[1 0];[1 0];[1 0];[1 0];[0.80 1];[1 0];[1 0];[1 0];[1 0];[0.77 1];[1 0];[1 0];[1 
0];[1 0];[0.59 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.58 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 
0];[0.67 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.61 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.73 0];[1 
0];[1 0];[1 0];[1 0];[1 0];[0.69 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.85 0];[1 0];[1 0];[1 0];[1 
0];[1 0];[0.70 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.88 0];[1 0];[1 0];[1 0];[1 0];[1 
0];[1 0];[0.61 0]]; 
% total IkBb in the cytoplasm 
data(5).ppn = 0; 
data(5).tdata = tdata .*60+ 2000*60; 
data(5).values = [[0.73 1];[1 0];[0.62 1];[1 0];[0.63 1];[1 0];[1 0];[0.50 1];[1 0];[1 
0];[0.38 1];[1 0];[1 0];[1 0];[1 0];[0.27 1];[1 0];[1 0];[1 0];[1 0];[0.27 1];[1 0];[1 0];[1 
0];[1 0];[0.23 1];[1 0];[1 0];[1 0];[1 0];[0.20 1];[1 0];[1 0];[1 0];[1 0];[0.22 1];[1 0];[1 
0];[1 0];[1 0];[0.43 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.38 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 
0];[0.53 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.49 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.64 0];[1 
0];[1 0];[1 0];[1 0];[1 0];[0.63 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.74 0];[1 0];[1 0];[1 0];[1 
0];[1 0];[0.67 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.86 0];[1 0];[1 0];[1 0];[1 0];[1 
0];[1 0];[0.70 0]]; 
 
%Experiment 2 
%NFkB in the nucleaus with DCPA treatment 
% 
data(2).ppn = 100; 
data(2).tdata = tdata.*60+2000*60; 
data(2).values = [[1 1];[1 0];[1 0];[1 0];[1.41 1];[1 0];[1 0];[6.60 1];[1 0];[1 0];[11.11 
1];[1 0];[1 0];[1 0];[1 0];[10.77 1];[1 0];[1 0];[1 0];[1 0];[6.01 1];[1 0];[1 0];[1 0];[1 
0];[6.21 1];[1 0];[1 0];[1 0];[1 0];[7.93 1];[1 0];[1 0];[1 0];[1 0];[9.30 1];[1 0];[1 0];[1 
0];[1 0];[7.49 0];[1 0];[1 0];[1 0];[1 0];[1 0];[5.72 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 
0];[5.75 0];[1 0];[1 0];[1 0];[1 0];[1 0];[8.80 0];[1 0];[1 0];[1 0];[1 0];[1 0];[7.60 0];[1 





0];[1 0];[8.18 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[7.78 0];[1 0];[1 0];[1 0];[1 0];[1 
0];[1 0];[9.20 0]]; 
% total IkBa in the cytoplasm 
% total IkBa in the cytoplasm 
data(4).ppn = 100; 
data(4).tdata = tdata .*60+ 2000*60; 
data(4).values = [[1.0 1];[1 0];[0.96 1];[1 0];[0.87 1];[1 0];[1 0];[0.38 1];[1 0];[1 0];[0.25 
1];[1 0];[1 0];[1 0];[1 0];[0.44 1];[1 0];[1 0];[1 0];[1 0];[0.93 1];[1 0];[1 0];[1 0];[1 
0];[0.73 1];[1 0];[1 0];[1 0];[1 0];[0.90 1];[1 0];[1 0];[1 0];[1 0];[0.64 1];[1 0];[1 0];[1 
0];[1 0];[0.57 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.56 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 
0];[0.63 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.57 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.62 0];[1 
0];[1 0];[1 0];[1 0];[1 0];[0.55 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.79 0];[1 0];[1 0];[1 0];[1 
0];[1 0];[0.60 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.58 0];[1 0];[1 0];[1 0];[1 0];[1 
0];[1 0];[0.55 0]]; 
% total IkBb in the cytoplasm 
% total IkBb in the cytoplasm 
data(6).ppn = 0; 
data(6).tdata = tdata .*60+ 2000*60; 
data(6).values = [[0.73 1];[1 0];[0.56 1];[1 0];[0.54 1];[1 0];[1 0];[0.43 1];[1 0];[1 
0];[0.28 1];[1 0];[1 0];[1 0];[1 0];[0.23 1];[1 0];[1 0];[1 0];[1 0];[0.22 1];[1 0];[1 0];[1 
0];[1 0];[0.20 1];[1 0];[1 0];[1 0];[1 0];[0.21 1];[1 0];[1 0];[1 0];[1 0];[0.23 1];[1 0];[1 
0];[1 0];[1 0];[0.34 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.34 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 
0];[0.43 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.43 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.47 0];[1 
0];[1 0];[1 0];[1 0];[1 0];[0.45 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.72 0];[1 0];[1 0];[1 0];[1 
0];[1 0];[0.65 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[1 0];[0.62 0];[1 0];[1 0];[1 0];[1 0];[1 










Supplement 3.1 : Gel image for IκBα in the cytoplasm 
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